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ABSTRACT 
Respiratory tract infections account for significant part of total illness 
episodes, physician consultations and days off from day care, school or work, 
thus incurring a significant personal and socio-economic burden. Viruses 
cause most of the acute infections of the respiratory tract, and there is lack of 
effective preventive and treatment options available against almost all of the 
over 200 different viral pathogens. Nutritional interventions are an 
increasingly researched option for reducing the infection burden, and of 
these probiotics are among the ones shown most promise. The aim of this 
work, consisting of three double-blind randomized controlled clinical trials 
in children and adults, was to investigate whether probiotic Lactobacillus 
rhamnosus GG would reduce the symptoms of respiratory tract infections 
and nasopharyngeal presence of respiratory viruses, as well as to explore 
factors hypothesized to have an impact on probiotic efficacy: the pharyngeal 
colonization of L. rhamnosus GG and the viability of the probiotic strain. 
 
In young adult tonsillectomy patients, L. rhamnosus GG was analysed from 
palatine tonsil samples and results compared to the faecal recovery of GG 
after three weeks’ daily consumption of placebo or L. rhamnosus GG as a 
single strain or as a part of a multispecies combination. L. rhamnosus GG 
was recovered in the tonsil tissue of 40% of the subjects in the GG group, 41% 
in the multispecies group and 30% in the placebo group. The results suggest 
that individual variation exists in the ability of the probiotic to adhere to the 
tonsil tissue, as the compliance of study product consumption was confirmed 
by the analysis of the faecal recovery of the strain and counting of leftover 
study products. Most of the subjects in the control group with L. rhamnosus 
GG harboured from the tonsil tissue had the strain recovered from the faecal 
sample already at the start of the intervention, indicating that persistent 
colonization could be a factor behind positive tonsillar recoveries in the 
control group. 
 
In a 28-week prospective trial on children aged 2–6 years attending day care 
in Finland, milk supplemented with L. rhamnosus GG was not able to reduce 
respiratory tract infections compared to the control group. Analysis on the 
completed cases subgroup, excluding subjects with intestinal L. rhamnosus 
GG colonization originating from outside the trial, suggested that children in 
the probiotic group had one day less per month with respiratory symptoms 
compared to the control group, but this exploratory finding warrants further 
research for confirmation. In a subgroup of children who visited the study 
physician due to an infection during the trial, the presence of 14 respiratory 
viruses was analysed from nasopharyngeal swab samples. L. rhamnosus GG 
did not reduce the occurrence of respiratory viruses, or the number of 
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infection symptoms observed at the time of the viral findings. In this 
subgroup of more symptomatic children, subjects in the probiotic group had 
fewer days with respiratory symptoms than children in the control group, but 
number of study physician visits was not different between the groups, thus 
suggesting that L. rhamnosus GG might be able to reduce only the symptoms 
of the less severe infections treated at home in the more symptomatic 
subjects.  
 
The potential of the experimental rhinovirus challenge model in studying 
probiotic efficacy in viral infections was tested in a 6-week trial on live and 
inactivated L. rhamnosus GG in adults. In this pilot study, the subjects were 
intranasally inoculated with experimental rhinovirus mid-intervention. 
Occurrence and severity of cold symptoms and number of subjects with 
positive rhinovirus culture and rhinovirus infection were the lowest in the 
group receiving live L. rhamnosus GG, but differences were not statistically 
significant. 
 
Taken together, L. rhamnosus GG was overall not effective in reducing the 
symptoms of respiratory tract infections, or occurrence of respiratory viruses 
in the nasopharynx of symptomatic children, but appeared to reduce 
symptoms in specific subgroups within the study cohort. It was 
demonstrated that L. rhamnosus GG can be recovered from the tonsil tissue 
of some but not all subjects after oral consumption, thus warranting future 
research on the role of the probiotic recovery in infection outcomes. The 
experimental rhinovirus model was demonstrated a potential controlled 
approach to studying the efficacy of probiotics, and the pilot study on the 
model indicated that live L. rhamnosus GG was more promising than the 
inactivated strain in reducing respiratory infections, but further research is 
needed to confirm the preliminary findings.  
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1 INTRODUCTION 
Acute infections of the respiratory tract place an enormous social and 
economic burden on families and societies. This is due to their frequency as 
well as mostly viral origin, meaning that there is lack of effective treatment 
options available. Of healthy population, children are most susceptible to 
respiratory tract infections (RTIs): they have two to five times as many 
episodes compared to adults per year. Viruses causing RTIs spread from 
person to person by direct contact with contagious secretions or by air in 
small particles. The symptoms start a few days after the infection. Common 
symptoms include runny and stuffy nose, sore throat, cough and fever. The 
severity and type of symptoms vary among different infective agents, 
individuals and population groups, for example fever being common in 
children but rare and mild in adults. In children, day care attendance is a 
well-identified risk factor (Grüber et al. 2008), whereas is adults stress 
(Stover 2010), smoking (Bilello 2005) and lack of sleep (Prather et al. 2015) 
can have an impact on infection occurrence. 
 
Majority of respiratory tract infections are mild and affect the upper 
respiratory tract, whereas infections in the lower respiratory tract are less 
frequent but often more severe.  Viruses are the most common aetiological 
agents in respiratory tract infections. Even though most cases are mild and 
self-limiting, they can also have serious consequences if the viral infection 
spreads outside the upper respiratory tract, or due to viral infection paving 
the way for other pathogens to enter the body, causing more severe illnesses 
(Heikkinen and Järvinen 2003). There are simple and effective preventive 
behavioural measures available, such as hand washing, to hinder the 
pathogens from spreading. For the viral infections, antiviral drugs have been 
successfully developed only against a few viruses. Unfortunately, many viral 
RTIs are still treated with antibiotics, even though positive progress has been 
made in recent years towards reducing this especially in paediatric 
populations (Donnelly et al. 2014; Lee et al. 2014). Antibiotic resistance, in 
which excessive and unnecessary use of antibiotics is a major causative 
factor, presents one of the biggest medical threats of the near future (Roca et 
al. 2015). 
 
As all individuals are susceptible to respiratory tract infections, nutritional 
strategies, that would have a low risk of adverse events and an easy 
incorporation into daily life, are appealing approaches to reducing the 
infection burden. Due to the frequency of the infections, even slight 
reduction in occurrence or amelioration of symptoms would be relevant on 
the population level, if adverse effects of the approach would be minimal. 
Probiotics have in recent years been evaluated as prominent nutritional 
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strategy to reduce respiratory tract infections (Hao et al. 2015; King et al. 
2014). However, results are still partially conflicting, it is unclear which 
probiotic strain is the most effective, and also mechanisms of probiotics in 
viral respiratory infections are not fully understood.  
 
The aim of this work was to clarify whether respiratory tract infections could 
be reduced in otherwise healthy children and adults by regular consumption 
of a widely researched probiotic strain, Lactobacillus rhamnosus GG (ATCC 
53103). Furthermore, the work aimed to gain understanding about 
mechanistic aspects, specifically on the probiotic colonization in the pharynx, 
on probiotics effect on nasopharyngeal viral findings during an infection, and 
on the role of the probiotic viability. 
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2 REVIEW OF THE LITERATURE 
2.1 RESPIRATORY TRACT INFECTIONS 
2.1.1 DEFINITIONS AND SYMPTOM PROFILES 
 
The common cold represents by far the majority of acute respiratory tract 
infection (RTI) cases. This generally mild illness is often linked to and shares 
similar symptoms with the other prevalent RTIs affecting the upper 
respiratory tract (maxillary sinusitis, acute otitis media, pharyngitis and 
laryngitis) and partially also with those affecting the lower respiratory tract 
(Table 1). The infections can be caused by multitude of viruses and also 
bacteria, and the exact aetiology can have an impact on the clinical 
manifestation of the disease (Heikkinen and Järvinen 2003). Usually most 
cases pass in two weeks, lower respiratory tract symptoms tending to last 
somewhat longer (Thompson et al. 2013). In the northern hemisphere, 
common seasonal pattern for most RTIs is to increase during the autumn 
towards peak incidence in the winter, and then decrease again in the spring. 
 
Table 1. Typical symptom profiles of common respiratory tract infections 
(Korppi and Järvinen 2011; Ruuskanen and Heikkinen 2011). 
 
 
 
The common cold  
The common cold is the term most often used by lay people when referring to 
a disease consisting of symptoms such as nasal discharge and stuffiness, 
sneezing, cough and sore throat (Heikkinen and Järvinen 2003). This term is 
widely used also in the medical literature, with acute nasopharyngitis and 
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rhinitis as the corresponding terms in the International Classification of 
Diseases (WHO 2016). The common cold is defined as an acute or mild 
infection of the upper respiratory tract, commonly self-limiting and most 
likely with viral origin (Allan and Arroll 2014; Heikkinen and Järvinen 
2003). Most common initial and rapidly passing symptom is sore throat, 
usually followed by runny and stuffy nose (peaking at 2-3 days from the start 
of the symptoms) and accompanied by cough that is typically at its worst on 
the fourth symptomatic day (Gwaltney et al. 2003). Rhinorrhoea usually lasts 
throughout the clinical manifestation of the disease, nasal secretions starting 
off as watery and turning thicker towards the end (Igarashi et al. 1993). Fever 
lasting 2-5 days is a common symptom of the common cold in children 
(Putto et al. 1986). Usually most symptoms clear off by the end of the first 
week of the illness. A systematic review recently concluded that by day 15 the 
common cold was resolved in 90% of the cases (Thompson et al. 2013).  
 
Acute sinusitis 
Sinusitis is an infection in one or more of the sinuses, which develops in 
approximately 5-10% of viral URIs (DeMuri and Wald 2013). Due to the 
condition most commonly occurring with viral rhinitis, it is also referred to 
as rhinosinusitis. In sinusitis, the membrane-lined air spaces around the 
nose, sinuses, become infected. Most often this is due to the common cold 
virus spreading to the sinuses and causing mucosal oedema. Sinusitis can 
also be a bacterial complication, but differentiation between viral and 
bacterial aetiology is not possible based on symptoms (Ah-See and Evans 
2007). Of the sinuses connected to the nasal passages (maxillary, frontal, 
ethmoidal and sphenoidal), maxillary sinuses are often affected by an 
infection. There are no reliable clinical criteria available to differentiate acute 
sinusitis from the common cold (Allan and Arroll 2014). Bacterial sinusitis 
can be suspected if symptoms of common cold show no sign of decreasing at 
10 days since onset (DeMuri and Wald 2013). Typical symptoms of acute 
sinusitis are runny and stuffy nose, reduced sense of smell, facial pain and 
facial pressure, sometimes accompanied with symptoms such as toothache in 
the upper teeth, malaise or pain on stooping (Ah-See and Evans 2007). Fever 
is often associated with sinusitis in children, but not commonly is adults 
(Eccles 2011). Sinusitis is considered acute when symptoms last for less than 
four weeks (Ah-See and Evans 2007).  
 
Acute otitis media 
Acute otitis media (AOM) is an infection in the middle ear, affecting mainly 
children. AOM always originates from a symptomatic viral infection of the 
upper respiratory tract (Nokso-Koivisto et al. 2015), and occurring in over 
60% of the cases in young children (Chonmaitree et al. 2008). In AOM, 
common cold symptoms are accompanied by more AOM-specific symptoms 
such as earache and lowered hearing (on average by 25 decibels). Earache 
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has traditionally been the hallmark symptom of AOM, but it is not 
necessarily present in all cases and neither is all earache caused by AOM 
(Blomgren and Pitkäranta 2005). Usually the complication occurs during the 
first week of the common cold episode (Kalu et al. 2011), and diagnoses of 
AOM are most commonly made on the third day from the cold symptom 
onset (Chonmaitree et al. 2008). 
 
Acute pharyngitis and tonsillitis 
Acute pharyngitis is an infection of the pharyngeal mucosa. When the 
primary site of the infection is tonsils, typically covered in light exudates, the 
condition is called acute tonsillitis. The most typical symptom of the 
infection is sore throat, causing difficulty in swallowing (Ebell et al. 2000). 
Cases with viral aetiology, associated with the common cold, are usually 
mild, with symptoms lasting only for a few days. In bacterial cases, 
accounting for 20-50% of the cases (Ebell et al. 2000), pain in the throat 
usually has a more abrupt onset and it is accompanied by fever, but 
differentiation of the aetiology based on symptoms alone is unreliable (Ebell 
et al. 2000; Wessels 2011).  
 
Acute laryngitis 
Acute laryngitis is an inflammation of the larynx, and it can be classified 
either as upper or lower respiratory tract infection. Typically laryngitis is 
preceded by common cold symptoms (Wood et al. 2014). The main 
symptoms of laryngitis include dry and barking cough, difficulty in breathing 
in, wheezing and voice disturbances. Upper part of the trachea is the tightest 
region in the upper respiratory tract of children, and thus swelling of the 
mucosa causes the difficulty in breathing.  In adults swelling occurs in the 
vocal chords, which leads to voice disturbances. However, in the majority of 
the cases symptoms are mild.  
 
Acute lower respiratory tract infections 
In adults, bronchitis and pneumonia are the most common infections 
affecting the lower respiratory tract, and the distinction between the two 
conditions is sometimes vague. In bronchitis the main airways of the lungs 
are infected, whereas in pneumonia pulmonary alveoli or interstitial tissue 
are affected. Both conditions have similar symptoms and cough as the main 
symptom, resulting from excess mucus production.  In children, infections 
affecting the lower respiratory tract are acute bronchitis, bronchiolitis, 
wheezing bronchitis, and pneumonia. Acute bronchitis is defined as cough 
associated with a viral infection, and it is the most common reason for cough 
in children (Tapiainen et al. 2016b). Bronchiolitis occurs in infants usually as 
apnoea and crepitations, whereas wheezing bronchitis occurs in toddlers 
(Tapiainen et al. 2016a).  
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2.1.2 EPIDEMIOLOGY 
 
For investigating the incidence of RTIs as a whole, register or hospital based 
studies are not sufficient in revealing the epidemiology of the full clinical 
spectrum (Anders et al. 2015) as many RTI cases are treated at home without 
medical consultation or prescribed medications (Gruber 1995). Therefore, 
the most relevant data on the incidence of RTIs comes from longitudinal 
community-based cohort studies (Anders et al. 2015; Selvaraj et al. 2014). 
Even with the cohort data, it should be highlighted how varying definitions 
make the available evidence difficult to summarize and synthesize (Roth et 
al. 2015), and also the methods of surveillance have an impact on the result 
(Shapiro 1998).  
 
Major data sets on the incidence of RTIs in high-income countries and 
community settings come from half a century ago. For example three large 
community-based studies were conducted in the US between 1940s and 
1970s (Tecumseh Study, the Seattle Virus Watch, and the New York Virus 
Watch), with varying methodology. These studies recorded 4.5-6.7 acute 
RTIs in children under one year of age, 4.9-8.0 in 1-4 –year-old children, 
3.0-6.2 in 5-9 -year-olds and 1.9-4.8 in 10-19 -year-olds (all frequencies per 
person-years) (Shapiro 1998). In a more recent longitudinal study, cohorts of 
households with children were followed for two full respiratory infection 
seasons (October to May), and were requested to report any cases of acute 
respiratory illnesses defined by two or more respiratory symptoms (Monto et 
al. 2014). The mean number of reported episodes in children was 1.1-1.4, 0.7-
0.8 and 0.5 in children under the age of five, 5-11 -year-olds and 12-17 -year-
olds, per season, respectively. In adults, the case numbers per season were 
0.6-0.8 and 0.4 cases in 18-49 -year-olds and over 50-year-olds, respectively. 
A cohort study following 294 children (enrolled at the age of 0.5-3 years) for 
a year documented 5.1 episodes of RTI in the upper respiratory tract per 
child-year with surveillance relying on parents’ initiative to contact the study 
centres when symptoms occurred (Chonmaitree et al. 2008). Another study 
following 3463 children from the age of three months to four years, showed 
RTI incidence of 3.8 per person year with a combination of passive and active 
surveillance (Lönnrot et al. 2015). A long prospective birth cohort following 
760 German children until age 12 years by means of a study diary filled out 
by parents found a mean annual number of 3.4, 2.3 and 1.1 respiratory 
infections in 0-2, 3-5 and 6-12 -year-olds, respectively (Grüber et al. 2008). 
Slightly lower numbers were reported in a follow-up study in Finland in the 
Finnish Otitis Media Cohort Study, where 329 healthy children were followed 
from two months to two years of age and parents were instructed to take the 
child to a study clinic in the case of symptoms of RTI in the upper respiratory 
tract for physician diagnosis (Nokso-Koivisto et al. 2002). During the study 
period, the median number of URI episodes was three for children cared for 
at home and six for children attending day care.  
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Taken together, different methodologies applied in the surveillance and 
categorization of RTIs make conclusions difficult to make, but it seems that 
today the incidence of acute RTIs in developed countries is between 2-5 
episodes per year in pre-school aged children, decreasing on average close to 
one annual episode in school-aged children and to less than one yearly 
episode in adults. In the German cohort following children from birth to up 
to 12 years of age, also the occurrence of specific diagnoses was detailed 
(Grüber et al. 2008). Rhinitis occurred 2.3, 1.3 and 0.8 times, bronchitis 
0.37, 0.32 and 0.07 times and AOM 0.31, 0.31 and 0.08 times annually in 0-
2, 3-5 and 6-12 year-olds, respectively. All other recorded RTI diagnoses 
(pharyngitis, tonsillitis, sinusitis, pneumonia, laryngitis or unspecified) 
occurred on average less than 0.2 times annually. Also higher occurrences of 
AOM complications have been documented for instance by Chonmaitree et 
al. (2008), who reported a mean number of 1.7 AOM episodes per child-year 
in 6-72 -month-olds. Despite the extremely low rate of diagnosed sinusitis by 
Grüber et al. (2008), changes in x-ray referring to viral sinusitis have been 
found in 39% of the adult common cold patients when measured on the 
seventh symptomatic day (Puhakka et al. 1998). Different sources have 
estimated that sinusitis is diagnosed in every tenth adult patient with RTI 
(Louie et al. 2005), and in young children, bacterial sinusitis develops in 8% 
of the patients (Marom et al. 2014). 
2.1.3 AETIOLOGY 
 
Viruses are by far the most common causative agents of RTIs, with 200 
different types of viruses known to cause infections. Frequently detected viral 
causes in RTIs are rhinovirus (RV), respiratory syncytial virus (RSV), 
influenza virus (IFV), parainfluenza virus (PIV), human metapneumovirus 
(MPV), adenovirus (AdV), coronavirus (CoV), human bocavirus (HBoV) and 
enterovirus (EV) (Nichols et al. 2008; Nokso-Koivisto et al. 2006). Of these, 
IFV, RSV, PIV and MPV are the most common viral pathogens in infections 
affecting the lower respiratory tract (Shi et al. 2015). RV is the most common 
respiratory virus in all age groups (Ruuskanen et al. 2013). The role of RV as 
the dominant causative agent in acute RTIs has been known since the 1960s, 
but knowledge of its importance further strengthened in the 1990s when 
polymerase chain reaction (PCR) techniques became widely available for 
virus detection and numbers of detected RV cases increased significantly 
(Ruuskanen et al. 2013). In otherwise healthy subjects, RV is associated with 
several clinical manifestations of RTIs: most significantly the common cold, 
but also AOM, sinusitis, pneumonia and bronchiolitis (Nichols et al. 2008; 
Ruuskanen et al. 2013). Subclinical infections are also common. Almost four 
out of five children have experienced at least one RV infection by the age of 
two (Blomqvist et al. 2002). RV infections peak in the fall and spring, but the 
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is some evidence that the RV cases occurring in the winter are more severe 
(Lee et al. 2012). No RTI symptoms can be directly associated to a specific 
virus so distinctly that a clinical diagnosis could be made based on it, but 
there are differences in the symptoms caused by different viruses (Nichols et 
al. 2008).  
 
Many viruses can cause the common cold, but RV is the dominant pathogen. 
In adults, RV was detected in half of the subjects during a common cold 
episode, with the highest rate of 92% detected during a fall outbreak (Mäkelä 
et al. 1998). In children, RV has been found in 71% of the uncomplicated 
common cold cases, followed by HBoV with 14%, AdV with 12% and EV with 
10% detection rates (Ruohola et al. 2009). HboV1 is only a decade ago 
discovered, persistent virus, that often appears as co-infection with other 
viruses, but recently it was confirmed that it also has an independent role in 
respiratory illness aetiology (Meriluoto et al. 2012). HboV2-4 have been 
discovered even more recently, and so far HboV2-3 have been associated 
with gastroenteritis (Berry et al. 2015). 
 
AOM is essentially a bacterial complication of the common cold, but 
nowadays viruses are known to play an important role in the aetiology as in 
5–10% of the cases no colonizing pathogenic bacteria can be detected 
(Nokso-Koivisto et al. 2015). A variety of viruses have a significant role in the 
aetiology of AOM, including RSV, AdV, CoV, EV, IFV, PIV and RV 
(Chonmaitree et al. 2008). In sinusitis, RSV, IFV and picornaviruses (EV, 
RV) have been detected (Louie et al. 2005). Bacterial aetiology is more rare 
than viral cause in sinusitis. Most common bacterial pathogens in both 
sinusitis and AOM are Streptococcus pneumoniae, Heamophilus influenzae 
and Moraxella catarrhalis. In pharyngitis, viruses have been detected in one 
third of the cases, bacteria in one fourth and both in one fifth of the cases 
(Esposito et al. 2004). Most common viral pathogens were RSV and AdV and 
most frequently detected bacterial pathogens Mycoplasma pneumoniae, S. 
pyogenes and Chlamydia pneumoniae. For tonsillitis, it has been estimated 
that virus may be the sole pathogen in one-third of all the cases (Nokso-
Koivisto et al. 2006), most commonly RV, CoV or PIV, and that the most 
common bacterial pathogen involved is group A beta-haemolytic 
streptococcus (Bird et al. 2014). Laryngitis is primarily a viral infection, with 
PIV, RSV, HBoV, RV, EV and IFV as common pathogens, PIV being the one 
most often detected (Rihkanen et al. 2008). 
 
Infections in the lower respiratory tract can be caused by all known 
respiratory viruses (Tapiainen et al. 2016a). In acute bronchitis, bacterial 
pathogens, most commonly S. pneumonia, have been detected in one fourth 
and viral pathogens, most commonly IFV, in one fifth of the cases in adults 
(Macfarlane et al. 2001). In children laryngitis, bronchitis, bronchiolitis and 
wheezing bronchitis are primarily viral infections, with RSV being the most 
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common virus detected in wheezing infants as well as in bronchiolitis, PIV in 
laryngitis and RV in wheezing children over one year of age (Tapiainen et al. 
2016a). Bacterial pathogen, either alone or with a virus, has been detected in 
15% of pneumonia cases in children (Jain et al. 2015a) and in 14% in adults 
(Jain et al. 2015b), the majority of cases being caused by viruses. RV and RSV 
were the most common viral findings in children, and RV and IFV in adults. 
2.1.4 PATHOGENESIS 
 
There are several different routes for respiratory viruses to spread: by direct 
contact with contagious secretions, by air in big or small particle aerosols, or 
by a combination of these routes (Heikkinen and Järvinen 2003). The most 
effective route of transmission differs between the viruses. RV can stay viable 
for several hours outside the body on contaminated surfaces (Winther et al. 
2011). It can spread effectively through infected nasal discharge getting on 
the hands of a person via direct contact with an infected person or via 
infected surfaces, and then from the hands of the recipient to the eyes or 
nose. IFV spreads well through small particle aerosols that are able to linger 
in the air for an extended time (Richard and Fouchier 2016), which is also a 
possible transmission route for RV (Dick et al. 1987). RSV was previously 
though to transmit mainly by large droplets or by self-inoculation (Hall and 
Douglas 1981), but more recent evidence suggests that small airborne 
particles can also serve as one transmission route for RSV (Lindsley et al. 
2010). 
 
The details on the pathogenesis of respiratory viruses are best documented 
for the most common pathogen, RV. It is not currently known if RV can 
penetrate an intact mucus covering nasal epithelial cells or if RV moves to 
the nasopharynx by mucociliary clearance (Winther 2011). Nonetheless, 
nasopharyngeal secretion is where the RV shedding is most frequently 
detected. Most RVs enter the human cells using intercellular adhesion 
receptor molecule 1 (ICAM-1) receptors, which are located mainly in the 
nasopharynx. Data is still conflicting on the importance of different 
replication sites in the nasopharynx, and whether the replication 
environments could have a role in symptom development (Kennedy et al. 
2012). However, due to the temperature sensitivity of RV, its replication is 
mainly restricted to the upper airways (Kennedy et al. 2012). RV infection 
does not destroy the epithelial barrier, like IFV and RSV infections do 
(Winther et al. 1990), but it does disrupt barrier function, which increases 
the permeability and translocation of pathogens (Kennedy et al. 2012).  
 
The host response, including both innate and adaptive immune systems, has 
a critical role in symptom development (Kirchberger et al. 2007). With the 
first encourter with the virus, engagement of the recognizing receptors 
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induces the first cytokine expression, that can restrict virus replication and 
modulate cytotoxic and natural killer (NK) cell activity (Kennedy et al. 2012). 
Replication of the virus releases inflammatory mediators, such as 
proinflammatory cytokines. These mediators attract inflammatory 
leukocytes, granulocytes, dendritic cells (DCs) and monocytes to the site of 
the infection, resulting in a continuum of inflammatory reactions that are 
responsible for the symptoms (Kirchberger et al. 2007). Findings showing 
that positive viral culture is a stronger indicator of a symptomatic disease 
than a molecular assay detection indicate that high viral load could have a 
role in symptom severity, as tissue culture is less sensitive than molecular 
methods and detects only live virus and likely only larger quantities 
(Chonmaitree et al. 2008). It was indeed recently shown that RV load 
positively correlated with symptom scores, when measured on second and 
fifth day after RV infection (Tapiovaara et al. 2016a). After the infection, 
serotype-specific antibodies develop in the majority of the infected to form 
an effective antiviral mechanism against future encounters with the virus 
(Kirchberger et al. 2007). However, as a whole immune response triggered 
by infection and recovery from the infection are still incompletely understood 
areas in research (Kirchberger et al. 2007).  
 
The time from an infection to symptom onset depends on the infecting virus, 
varying from half a day to six days (Lessler et al. 2009). In a systematic 
review pooling the available data for common respiratory viruses, it was 
found that median incubation time was 0.6 days for IFV B, 1.4 days for IFV 
A, 1.9 days for RV, 2.6 days for PIV, 3.2 for CoV, 4.4 days for RSV and 5.6 
days for ADV (Lessler et al. 2009). The symptoms of infection also vary 
depending on the causative agent. Associations have been suggested between 
fever and IFV, MPV, CoV and PIV (Uitti et al. 2015). Rhinitis, nasal 
congestion and cough have demonstrated positive association with M. 
catarrhalis, and cough with RSV and PIVs in the same study. The fact that 
practically all respiratory viruses cause nasal symptoms is a likely reason for 
specific respiratory viruses not standing out in the multivariable models. 
 
Virus infection can also facilitate later invasion bacterial pathogens 
(Hendaus et al. 2015). For example physical damage to the mucosa of the 
nasopharynx caused by IFV infection can weaken the local defence against 
bacteria, leading to more bacteria being able to translocate through the 
respiratory cell epithelial barrier. Bacterial adherence is also facilitated by 
viral infection upregulating the receptors utilized by bacteria. In AOM, 
dysfunction of the eustachian tube, passage connecting nasopharynx to the 
middle ear, can allow pathogens to access the middle ear to reproduce and 
cause local inflammation (Nokso-Koivisto et al. 2015). Bacterial 
complications of viral infections affecting the upper respiratory tract as a 
whole are in any case rare. In subjects with the common cold, rise in 
antibodies to bacterial pathogens occurred in only 3.5% of the cases, and in 
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most cases coinfection with a virus was also detected (Mäkelä et al. 1998). In 
hospitalized patients viral and bacterial coinfection compared to viral 
infection alone did not substantially affect the severity of the illness 
(Damasio et al. 2015). 
2.1.5 DIAGNOSTICS 
 
Clinical diagnostics 
The diagnostic criteria of respiratory infections are not strict, which can leave 
physicians uncertain of the diagnosis (Blomgren and Pitkäranta 2005). 
Classification of acute RTIs according to World Health organizations (WHO) 
International Classification of Diseases (ICD-10) (WHO 2016) has been 
argued to be the area leaving most freedom for physicians on how to code a 
condition (Beckman 2014). Major challenge in diagnostics and clinical 
management of RTIs remains in the differentiation of uncomplicated viral 
infections from those with bacterial aetiology and thus indication for 
antimicrobial treatment (Zumla et al. 2014).   
 
Diagnosis of the common cold can be simply done based on the clinical 
manifestation of the disease, and adult patients can even self-diagnose the 
common cold reliably (Heikkinen and Järvinen 2003). Examination of the 
viral aetiology is rarely needed as the virological diagnosis has no significant 
implication for the course of the disease or the treatment (Tregoning and 
Schwarze 2010). However, in the case of IFV for which antiviral medication 
is available, early identification of the aetiology is needed, as the possible 
treatment needs to be initiated during the first symptomatic days for it to be 
effective (Tapiainen et al. 2016a). Infections caused by the IFV cannot be 
differentiated based on the symptoms alone, and therefore virology needs to 
be tested for diagnosis. Diagnosis of sinusitis is most often done based on 
clinical signs and symptoms, the most typical symptom pattern being lack of 
improvement in the cold symptoms in 10 days (DeMuri and Wald 2013). 
Diagnosis of AOM relies on the inspection of the eardrum, and AOM can be 
accurately diagnosed based on signs and symptoms combined with 
tympanometry and pneumatic otoscopy (Blomgren and Pitkäranta 2005).  
 
Fever as an early symptom of infection in children is challenging, as it can be 
caused by the common cold but it can also be an indication of a severe 
bacterial infection (Heikkinen and Järvinen 2003). Sore throat is a typical 
symptom of both the common cold and streptococcal pharyngitis. Presence 
of runny or stuffy nose usually differentiates the two conditions, but for 
instance in Finland laboratory testing for group A streptococcal infection is 
recommended (Käypä Hoito working group 2013), whereas for example in 
the UK clinical diagnosis is considered sufficient (Bird et al. 2014). 
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Laryngitis, bronchitis and bronchiolitis in children are diagnosed based on 
clinical signs and symptoms as bacteria are an uncommon cause in all the 
conditions (Tapiainen et al. 2016a). Pneumonia can also be diagnosed 
indirectly based on clinical findings (Tapiainen et al. 2016b).  
 
Laboratory diagnostics 
Respiratory pathogen identification can be done from many different 
samples, such as nasopharyngeal aspirates, washes and swabs (alone or 
together with oropharyngeal swabs) as well as sputum, tracheal aspirates and 
bronchoalveolar lavages, and the type of sample can significantly affect the 
sensitivity and specificity of the pathogen detection (Passioti et al. 2014). 
Even though current available options for determining the pathogen in 
clinical practise are limited, due to e.g. challenges in availability and turn-
around time (Zaas et al. 2014), major development has taken place in 
laboratory diagnostics of pathogens causing respiratory infections during the 
past decades. Bacterial diagnostic tests are more challenging, and culture 
remains the gold standard of bacterial identification, despite it taking several 
days (Zaas et al. 2014). Of the common respiratory bacteria, antigen testing 
is available for S. pneumoniae and group A Streptococcus. In terms of viral 
pathogens, point-of-care rapid antigen tests are available for the detection of 
IFV and RSV. Point-of-care test able to detect antigens from altogether eight 
respiratory viruses (IFV A and B, RSV, ADV, MPV, PIV1-3) as well as 
Streptococcus pneumonia has also been developed (Sanbonmatsu-Gámez et 
al. 2015). The molecular detection of respiratory pathogens is more feasible 
for viruses than for bacteria (Zaas et al. 2014). In the laboratory diagnosis of 
viral infection, PCR has for large part replaced the preceding methods, such 
as virus isolation in tissue culture and immunological methods detecting 
antibodies and antigens (e.g. enzyme linked immunoabsorbent assay 
(ELISA), direct and indirect immunofluorescence (IF) assays). PCR 
techniques are sensitive and relatively quick, with time from sample 
collection to results taking 2-24 hours. Development of multiplex PCR tests, 
able to detect several pathogens in one run with short throughput time, has 
further eased the viral detection (Zumla et al. 2014). Challenge from the 
clinical perspective remains in the fact that co-infections of both virus and 
bacteria can occur, and thus the detection of a virus does not rule out a 
concomitant bacterial infection. Furthermore, even multiplex PCR assays can 
miss virus detection, e.g. in the case of a mutated or novel virus, due to the 
assay being limited to the specific viruses included on the panel. Also losses 
in sensitivity have been reported when multiplex assays have been compared 
to singleplex assays in respiratory virus detection (Parker et al. 2015).   
Analysis of the host response via gene activation and suppression in blood 
samples for distinguishing bacterial infections from those caused by viruses 
is currently an actively researched area and potential diagnostic tool for the 
future (Herberg et al. 2016; Mahajan et al. 2016). 
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2.1.6 TREATMENT 
 
Due to the multitude of pathogens causing RTIs, the development of a 
universal effective treatment is unlikely (Heikkinen and Järvinen 2003). 
Attempts to develop drugs targeting all phases of the life cycle of specific 
respiratory viruses have been numerous, but few have been successful 
(Passioti et al. 2014). To date, of all the respiratory viruses causing RTIs, 
antiviral drugs have been successfully developed only against IFV and RSV 
(De Clercq and Li 2016). Neudamidase inhibitors can shorten the 
symptomatic period of IFV A and B infections on average by one day, 
symptoms may occur as less severe, and clinically meaningful reductions in 
complications measured by antibiotic treatments and hospitalizations have 
been achieved (Nguyen-Van-Tam et al. 2015). Challenge is that the treatment 
needs to start within two days from symptom onset, and data is also still very 
limited in regard to the treatment of children. Due to the rather modest 
effects, it has been suggested that the neuraminidase inhibitors should only 
be used in patients with a high risk of complications or who are markedly 
unwell. Ribavirin has shown to be active against both RSV and IFV, and is 
currently the only approved antiviral treatment in RSV-infections (Passioti et 
al. 2014). However, it is not in routine clinical use as only minimal clinical 
benefit has been demonstrated in reducing the duration of severe 
complications (Drysdale et al. 2016).  Rapid development is currently 
ongoing in RSV drug development, and human challenge studies have shown 
promising results at least for two novel drug candidates, GS-5806 
(DeVincenzo et al. 2014) and ALS-008176 (DeVincenzo et al. 2015). 
 
Even though antibiotics are effective in the treatment of bacterial infections, 
challenges in their use in RTIs arise from the distinction of bacterial 
infections from those caused by viruses and many RTIs passing also without 
antibiotic treatment, and on the other hand from the clear need to avoid 
unnecessary antibiotic treatments due to the increasing antimicrobial 
resistance (Roca et al. 2015) and risk for adverse effects (Kenealy and Arroll 
2013). Even though antibiotics are not effective against viruses, it was long 
thought that secondary bacterial infections could be prevented by prescribing 
antibiotics in viral RTIs, but there is no evidence to support this and it is thus 
not recommended (Kenealy and Arroll 2013). Sinusitis is commonly treated 
with antibiotics, even though 80% of sinusitis cases pass in two weeks 
without antibiotic treatment (Ahovuo-Saloranta et al. 2014). In the treatment 
of mild AOM, the expectant observational approach is often justified in terms 
of antibiotic treatment as most cases pass without treatment (Venekamp et 
al. 2015). Antibiotics show only modest benefit in the treatment of the sore 
throat, but when pharyngitis or tonsillitis have group A Streptococcus 
confirmed as the pathogen, the benefit of antibiotic treatment increases (van 
Driel et al. 2013). Antibiotics have no or very limited benefits in the 
treatment of laryngitis (Reveiz and Cardona 2015), bronchitis (Smith et al. 
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2014a) or bronchiolitis (Farley et al. 2014), which both have primarily viral 
aetiology. Pneumonia is treated with antibiotics (Prina et al. 2015). 
 
Symptom-alleviating pharmaceuticals 
Due to the lack of effective treatment options available for viral RTIs, the 
focus is in symptom alleviation. Adequate analgesia should be the priority in 
the treatment of all RTIs (Venekamp et al. 2015). Non-steroidal anti-
inflammatory drugs, such as ibuprofen, can reduce pain associated with the 
common cold, such as head or ear ache, as well as sneezing, but are not 
effective in reducing the total symptom load (Kim et al. 2013). 
Acetaminophen (paracetamol) provides mild analgesia , and has shown to be 
more effective than placebo but less effective than ibuprofen in reducing 
fever in children (Allan and Arroll 2014). Also several other symptom-
relieving medications and their combinations are commonly used in RTIs, 
but with varying data on their effects. Antihistamine-decongestant-analgesic 
combinations may provide some alleviation for the common cold symptoms 
(De Sutter et al. 2012). Antihistamine with decongestant was the most 
effective of the evaluated combinations, especially in regard to severity of 
sneezing, but it also increased the adverse events such as nasal dryness and 
insomnia. Nasal obstruction was relieved slightly with the combinations 
containing a decongestant. Rhinorrhoea and cough were reduced slightly 
with antihistamine-decongestant-analgesic. All effects on single symptoms 
were less than one point on 4-5 point severity scales. Both antihistamine and 
decongestants alone have reached statistical significance in reducing some 
nasal symptoms, but relevance of minor decreases (e.g. 0.3 or less in 4-5 
point scales for antihistamine) have been questioned from clinical 
perspective (Allan and Arroll 2014). Available data on decongestants or 
antihistamines in children do not support their use in acute sinusitis (Shaikh 
and Wald 2014) or in AOM (Coleman and Moore 2008). For intranasal 
corticosteroids only limited data is available, but currently there is no 
indication that they would be effective in alleviating the symptoms of the 
common cold (Hayward et al. 2012). Intranasal ipatropium bromide, an 
anticholinergic drug, has shown no effect on nasal congestion, but can 
alleviate runny nose (AlBalawi et al. 2013). Adverse events, such as nasal 
dryness, are commonly associated with the use of the drug intranasally. 
There is no good-quality evidence on the benefits of prescription-free 
medicines for acute cough (Smith et al. 2014b). Vapor rub, including 
camphor, menthol and eucalyptus oil, applied to the neck and chest has in 
one study showed modest improvement in sleep and cold symptoms (Paul et 
al. 2010).  
 
Nutritional approaches  
Several nutritional approaches have been researched on their potential in 
relieving RTI symptoms. In a meta-analysis of seven studies addressing 
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therapeutic vitamin C consumption, started only after the onset of symptoms 
(1-8 g per day once or for several days), vitamin C supplementation was 
concluded ineffective. A meta-analysis of 14 trials (13 in adults and one in 
children) showed that oral zinc supplementation started one or two days 
from symptom onset had no effect on symptom severity, but it shortened 
cold duration (Das and Singh 2014). The effect was more evident with high 
doses (at least 75 mg daily). However, adverse events, such as nausea, have 
been significantly higher in the zinc groups, which hinder the potential of 
zinc usability. Out of the six studies conducted on Echinacea preparations in 
shortening the durations of the common cold symptoms, only two have 
showed positive results (Karsch-Völk et al. 2014). A single daily dose of 
honey at bedtime showed weak positive effect on acute cough in children in a 
two-trial meta-analysis, but high risk of bias in the trials did not allow 
drawing of firm conclusions (Oduwole et al. 2012). Also the use of Chinese 
medicinal herbs for the treatment of sore throat has been evaluated, and a 
weak positive impact has been discovered, but with methodological criticism 
raised regarding the evaluated trials (Huang et al. 2012).  
 
Other interventions 
Five clinical trials conducted on adults and children have compared the use 
of nasal irrigation to routine care or use of nose sprays (King et al. 2015). 
Trials have methodological issues, but evidence points in the direction that 
nasal saline irrigation could reduce nasal secretion and obstruction in acute 
infections of the upper respiratory tract, even though more well-conducted 
trials are needed to confirm this. It has also been suggested that by breathing 
of humidified air, the steam could help congested mucus to drain better, and 
thus relieve symptoms. Recent review summarizing the findings from six 
trials concluded that the benefits of steam inhalation in the treatment of the 
common cold were inconsistent (Singh and Singh 2013). One study has 
indicated a lack of beneficial effects of mist therapy in bronchiolitis in 
children (Umoren et al. 2011). Mist has been concluded to be ineffective in 
reducing the symptoms of laryngitis in children (Tapiainen et al. 2016a). 
2.1.7 GENERAL RISK FACTORS AND PREVENTION 
 
Young age is a clear risk factor in RTIs, as the incidence of illness is highest 
in children under the age of two.  Full breastfeeding for at least six months 
compared to only four months appears to reduce pneumonia and recurrent 
AOM (Chantry et al. 2006). Day-care attendance increases the frequency of 
common cold (Ball et al. 2002; Nokso-Koivisto et al. 2002). However, the 
attendance in large day care might serve as a protective factor against RTIs in 
school age, with difference evening out by teenage (Ball et al. 2002). Parental 
smoking significantly increases the risk of infections affecting the lower 
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respiratory tract in children (Jones et al. 2011). In adults, smoking (Bilello 
2005), stress (Stover 2010) and short sleep (Prather et al. 2015) might 
increase susceptibility to the common cold, whereas interestingly positive 
emotional style has been shown to increase resistance to illness (Cohen et al. 
2006). The evidence on the role of exercise is inconclusive (Grande et al. 
2015). It has also been suggested that individual airway microbiota 
(Hasegawa and Camargo 2015) and genetic factors (Tregoning and Schwarze 
2010) might have a role in respiratory infection susceptibility. 
 
Many physical interventions, most importantly hand washing, especially 
around young children, and the use of surgical masks, have been shown to 
effectively reduce the spread of respiratory viruses (Jefferson et al. 2011). It 
has also been shown that ethanol hand rub is not as effective as hand 
washing with soap and water against RV (Savolainen-Kopra et al. 2012). One 
trial has shown that gargling with water decreases the number of RTI 
episodes significantly (Satomura et al. 2005).  
 
Immunization 
For respiratory viruses, globally available vaccine exists only against IFV. In 
2-6 -year-old children benefit of vaccination is clear, with six children 
needing to be vaccinated to prevent one influenza case (Jefferson et al. 2012). 
In older children 28 need to be vaccinated to prevent one case, and there is 
lack of evidence on the effectiveness in under 2-year-olds. In healthy adults 
influenza vaccination has been concluded to have limited benefits (Jefferson 
et al. 2014). The pooling of data in meta-analyses from several influenza 
vaccination trials can, however, be criticized. Details of individual trials in 
both children and adults show that when the antigen match between the 
circulating strains and those in the vaccine has been good, has the vaccine 
effectiveness also been high (Heikkinen et al. 2013). Furthermore, influenza 
vaccination has significantly reduced also the incidence of AOM in small 
children (Ozgur et al. 2006). In terms of bacterial pathogens, the 
introduction of pneumococcal vaccines has reduced not just pneumonia, but 
also AOM cases (Yildirim et al. 2015), for instance AOM decreasing by 6-8% 
in vaccinated children compared to controls (Nokso-Koivisto et al. 2006). 
There is on-going research to develop vaccines against several other 
respiratory viruses (e.g. RSV, RV, and PIV), but attempts have not yet been 
successful.  
 
Nutritional interventions  
A meta-analysis summarizing 11 placebo-controlled clinical trials on vitamin 
D found a protective affect against respiratory infections (range for number 
needed to treat 9-33), with daily doses showing a better response compared 
to large doses at long intervals (Bergman et al. 2013). A meta-analysis 
including 29 trials concluded that regular vitamin C supplementation does 
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not prevent colds in the general population, but it might e able to do so in 
heavily exercising adults (Hemilä and Chalker 2013). However, the same 
meta-analysis concluded that, based on 32 studies, regular vitamin C 
consumption (dose at least 0.2 g per day) can shorten the duration of 
common cold on average by 8% in adults and by 14% in children, and also 
decrease symptom severity (Hemilä and Chalker 2013). Prophylactic trials on 
Echinacea products have shown consistent albeit non-significant preventive 
trends in the 12 conducted trials, thus indicating some effect but with 
debatable clinical significance (Karsch-Völk et al. 2014). A meta-analysis on 
the prophylactic use of xylitol in the prevention of AOM in children pooled 
data from four trials with adequate methodological quality, and concluded 
that xylitol may reduce the occurrence of AOM by 25% (Azarpazhooh et al. 
2011). 
 
Reaserch data on other potential components is more limited or conflicting. 
When supplementation of zinc was started in children at the onset of cold 
season, pooled data from two trials showed a cold incidence of 38% in the 
zinc group and 62% in the control group (Das and Singh 2014). Evidence is 
mixed regarding the benefit of zinc supplementation in the prevention of 
AOM (Gulani and Sachdev 2012). Effect of specific prebiotic 
supplementations on RTI outcomes has been addressed in two trials. 
Galacto-oligosaccharide-polydextrose-supplementation in preterm infants 
during the first two months of life was recently shown to lower the number of 
RTIs and specifically RV infections, compared to the control group during 
the one-year follow-up, and the benefits outweighed those achieved with 
probiotic Lactobacillus rhamnosus GG supplementation (Luoto et al. 2014). 
Earlier 6-month trial on term infants receiving an infant formula 
supplemented with a galacto-oligosaccharide-fructo-oligosaccharide 
combination, a tendency towards fewer infections in the upper respiratory 
tract in the prebiotic formula group compared to the control formula group 
was reported (Arslanoglu et al. 2007). Existing data for garlic in the common 
cold was also recently evaluated, with only one trial meeting the quality 
criteria (Lissiman et al. 2014). The one study suggested that garlic might be 
able to lower the occurrence of the common cold, but more research is 
needed to confirm this initial finding. Ginseng has also been studied for its 
ability to reduce the incidence of colds, but data is still limited to draw 
conclusions on its efficacy (Seida et al. 2011). There is indication that when 
taken preventatively, ginseng might shorten the duration of a cold, but the 
methodological quality of the studies has been questioned (Allan and Arroll 
2014) and thus confirmatory trials are required. One clinical trial has studied 
the effect of bovine lactoferrin and whey protein immunoglobulin (Ig) -rich 
fraction on cold incidence (Vitetta et al. 2013). In this study, the treatment 
group experienced significantly less cold symptoms and episodes of cold 
compared to the control group, but no statistically significant difference was 
seen on the duration or severity of colds. 
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2.1.8 SOCIAL AND ECONOMIC IMPACT  
 
In the latest Global Burden of Disease study from 2013, RTIs accounted for 
4.8% of the total health lost when measured by disability-adjusted life years 
(Murray et al. 2015). Of this share 96% is attributed to infections in the lower 
respiratory tract, which are the third leading cause of disability-adjusted life 
years globally. Due to the disease burden and high incidence especially in 
children, the challenges associated with the infections are significant. Work 
or school absenteeism is the most evident social impact. In addition to this, 
due to the often mild nature of the illness, people may attempt to continue 
their lives normally by going to work or school. It has been suggested that 
RTIs cause reduced alertness and thus lower performance in some tasks 
(Smith 2013), which can have implications that are beyond the reach of the 
absenteeism measurements.  
 
Even if RTIs are largely benign, due to the high incidence the economic 
consequences are significant, although very limited data is available on the 
financial burden. In the UK, it has been roughly estimated back in 2004 that 
the primary care costs of upper RTIs would be £31 million (Urquhart and 
McKenzie 2004). This estimation was a result of calculation taking into 
consideration the average number (value of 6-8 per year used), the frequency 
of taking the child to a physician when child is unwell (11%), a consultation 
cost estimation (£16) and the preschool population of 2.94 million in the UK 
at the time. In Finland, the economic consequences of illness in day care 
centres was estimated in 1990 (Nurmi et al.). In this evaluation infectious 
diseases in total caused 90% of illnesses and costs. The link between day care 
attendance, compared to other forms of care, and tendency to use more 
health care services has also been made (Silverstein et al. 2003).  In Finland 
in 1999 it was estimated that each episode of AOM costs $228 in children 
attending day care (Niemelä et al. 1999). 
 
2.2 PROBIOTICS  
2.2.1 DEFINITION AND PROPERTIES  
 
Food and agriculture organization (FAO) and WHO expert consultation 
group has defined probiotics as “Live microorganisms which when 
administered in adequate amounts confer a health benefit on the host” (FAO 
and WHO 2006). A recent consensus statement from the International 
Scientific Association for Probiotics and Prebiotics reinforced the definition 
as sufficiently accommodating also for anticipated future applications (Hill et 
al. 2014). Microbes from many genera have been identified as probiotics, but 
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Lactobacillus and Bifidobacterium have to date been the most commonly 
studied and used in food products and supplements. Probiotic strains should 
be able to survive and proliferate in the acidic conditions of the upper 
gastrointestinal (GI) tract created by bile and gastric juices (FAO and WHO 
2006). It has further been specified that probiotics should demonstrate 
adhesive properties to human tissues, stimulate the immune system, protect 
the host from pathogens and beneficially affect host’s microbiota (Giraffa et 
al. 2010). Finally, probiotics should naturally be safe to consume, have no 
pathogenic or virulence properties and lack transferable antibiotic resistance 
(FAO and WHO 2006).  
 
All probiotic strains are unique in their potential health benefits, and even 
strains belonging to the same species are known to confer different effects. 
Lactobacillus rhamnosus GG (GG) is one of the most researched probiotic 
strains worldwide, and it is available for consumers all over the world in 
numerous food products and supplements. GG was isolated from a faecal 
sample of a healthy human in the early 1980s. Its discoverers tested a 
number of Lactobacillus strains isolated from faecal samples for resistance to 
acid and bile, adherence to intestinal epithelial cells, production of 
antimicrobial substances and for their growth rate (Doron et al. 2005). Of the 
tested strains, GG possessed all the critical properties and demonstrated the 
highest growth rate. Since then, a multitude of studies have addressed the 
probiotic properties and health effects of GG. To date, most evidence on the 
health benefits of GG exist for atopic dermatitis (Foolad and Armstrong 
2014), acute diarrhoea (Guandalini 2011) and antibiotic-associated diarrhoea 
(AAD) (Szajewska and Kołodziej 2015).  
2.2.2 GENERAL MECHANISMS OF ACTION 
 
It is believed that probiotic strains do not become permanent residents of the 
hosts’ intestinal microbiota (Corthésy et al. 2007). For the probiotic to be 
able to interact with the host and affect both the non-immune defence, e.g. 
the competitive exclusion of pathogens, and the immune system, adhesion to 
mucosal surfaces is of importance (Bermudez-Brito et al. 2012; Collado et al. 
2007). Relatively recently, in genomic analysis of GG, fimbria-like surface 
structures, pili, were found to be essential for the adhesion of the probiotic to 
human intestinal mucus (Kankainen et al. 2009). Clinical trials on GG have 
demonstrated high levels of adhesion and persistence by analysing the 
recovery of the strain in GI mucosa. Adherence to intestinal mucosa has been 
demonstrated in colonic biopsies for GG after 12 days of consumption 
(Alander et al. 1997), and the temporary colonization was shown to remain 
for over a week after GG administration (Alander et al. 1999). In a study on a 
combination of Lactobacillus johnsonii La1 and Bifidobacterium longum 
BB536, administered twice daily for three days at two different doses, the 
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Lactobacillus strain was recovered from the colonic mucosa samples in 60% 
of the subjects with the higher dose and in 27% of the subjects with the lower 
dose, whereas the bifidobacterium strain could not be recovered from the 
mucosa (Gianotti et al. 2010). For nasopharyngeal adhesion, a trial on 40 
children given GG for three weeks before adenotomy, GG was recovered from 
the adenoid tissue in all children receiving GG, but also in 76% of the 
children in the control group (Swanljung et al. 2015). Also one pilot study on 
six subjects demonstrated that oral consumption of L. plantarum DSM 9843 
led to the recovery of the strain from a tonsil surface four hours after intake 
in all subjects, but after eight hours in only one of the subjects (Stjernquist-
Desatnik et al. 2000). Furthermore, a non-randomized and non-controlled 
10 day intervention trial on S. salivarius K12 showed that the strain could be 
recovered in only one out of 19 nasopharyngeal swab (NPS) samples, and in 
three out of seven adenoid samples (Power et al. 2008). GG has also been 
recovered from vaginal epithelium in one tenth of the subjects (Colodner et 
al. 2003), from the oral cavity in two thirds of the participants (Yli-Knuuttila 
et al. 2006) and from the middle ear effusion samples in one fifth of the 
subjects (Tapiovaara et al. 2014) after oral consumption of the probiotic. 
 
Even though understanding of how probiotics generate their beneficial 
effects is not yet complete, it is known that effects are triggered through a 
combination of several different probiotic-host interactions. Figure 1 
provides an overall framework of probiotic actions, but it is worth noting that 
strain-to-strain variations can be significant and that mediation of each 
health effect is likely to be a multifactorial process with mechanism profile 
differing between conditions.  It is likely that some mechanisms of action are 
shared among all strains in specific genera, some among those belonging to 
the same species, while some mechanisms are strain-specific (Hill et al. 
2014). For GG, several microbe-associated molecular patterns (MAMPs) 
have been identified, such as lipoteichoic acid molecules, secreted proteins, 
exopolysaccharides and specific DNA motifs. Using MAMPs, GG can 
communicate with the host via specific pattern recognition receptors (PRRs) 
located in epithelial and immune cells (Segers and Lebeer 2014; Wells 2011).  
 
Mechanisms of probiotics can be broadly categorized into three classes: 
exclusion or inhibition of pathogens directly or via modification of the 
commensal microbiota, enhancement of the epithelial barrier function and 
modulation of the host immune responses (Figure 1). These mechanisms 
have been demonstrated to a large extent using in vitro and animal models, 
thus more in vivo human data is needed to substantiate their role in the 
interaction with the host. Molecular profiling can offer insight of the complex 
host responses modulated via combinations of for instance different MAMP-
PRR interactions and metabolites in vivo. For GG, host response studies 
have demonstrated effects on immune response and inflammation by gene 
expression analysis (Di Caro et al. 2005) and induction of the Th1 response 
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by transcriptome analysis (van Baarlen et al. 2011) in the intestinal mucosa. 
Human mucosal transcriptome responses have, however, indicated that 
there is person-to-person variation in how probiotics affect the host, and it is 
suggested that genetic background, host microbiota as well as general 
lifestyle and diet could affect responsiveness to probiotics (van Baarlen et al. 
2011). More in vivo research is needed to understand the determinants for 
responders and non-responders, although this can be a difficult task due to 
the observed inter-person variations in strategies for accomplishing mucosal 
homeostasis (Bron et al. 2012).  
 
 
 
Figure 1. General mechanisms of action of probiotic bacteria (Bermudez-
Brito et al. 2012; Lebeer et al. 2008; Segers and Lebeer 2014; Wells 2011).  
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2.2.3 PRODUCT MATRIX  
 
When probiotic strain is added to a food product, further criteria are that the 
strain should not negatively affect the taste and it should survive the 
processing and storage conditions (Lee and Salminen 1995). Probiotics are 
most commonly consumed in milk products or as supplements, but also 
several other food products with probiotics exist on the market, such as 
juices and cereal products (Vijaya Kumar et al. 2015). The food product 
matrix can potentially protect probiotic strain in the GI environment. The 
protective properties of milk as a matrix are best documented, whereas the 
properties of non-dairy food matrixes with shorter history of use are less 
known (Vijaya Kumar et al. 2015).  
 
A study on a four-strain probiotic combination (GG, L. rhamnosus Lc705, P. 
freudenreichii subspecies (subsp.) shermanii JS, and B. animalis subsp. 
lactis Bb12) showed that within the studied matrixes (yoghurt, cheese, 
capsule), the matrix did not have an impact on the faecal recovery of 
lactobacilli, but it did affect the faecal quantity of propionibacteria and 
bifidobacteria, which were the lowest after the consumption of the probiotic 
cheese (Saxelin et al. 2010). A study on L. plantarum strain found that strain 
was recovered from faecal samples in higher amounts when consumed in 
fermented sausage compared to freeze-dried powder (Klingberg and Budde 
2006). For B. animalis DN-173010, fermented milk and freeze-dried powder 
were equally good matrixes when measured by the faecal recovery of the 
strain (Rochet et al. 2008).  
 
In terms of probiotic properties, an in vitro study on GG comparing different 
product matrixes and sources of the strain, no significant differences were 
found in the adhesion abilities, but pathogen exclusion by inhibition and 
competition varied significantly among the different isolates (Grześkowiak et 
al. 2011). For instance for pili, key adhesive structures in GG, industrial 
production procedures can be detrimental (Segers and Lebeer 2014). 
Industrial cultivations and production processes can for instance lead to the 
production of pilus-less GG if the genomic island carrying the pilus gene 
locus gets deleted during processing (Sybesma et al. 2013). These findings 
highlight that the product matrix and quality control of production are issues 
that should be taken into consideration also when human intervention 
studies are discussed and results interpreted. 
 
In recent years, microencapsulation of probiotics has been suggested as a 
way to tackle the challenges of probiotic survival and stability both in the 
food product and in the GI tract (Islam et al. 2010). This approach would 
eliminate the possibility for local effects in the oral cavity and pharynx. Also 
growing interest has been targeted towards inactivated forms of the probiotic 
strains, which would tackle the same challenges. Furthermore, few trials 
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have administered probiotics in nasal spray instead of delivery via a food 
product or a supplement (Santagati et al. 2015; Skovbjerg et al. 2009). This 
approach has been well tolerated in subjects but health effects are yet to be 
studied. 
 
2.2.4 VIABILITY 
 
The often cited FAO&WHO definition (FAO and WHO 2006) includes a 
notion of the viability of the probiotic, and the ability of the strain to survive 
alive and grow in the harsh GI conditions is further emphasized in the critical 
properties of probiotics. Yet, there is uncertainty regarding how critical 
viability of the strain is for delivering the beneficial health effects. During the 
past decade, several in vitro and animal studies have compared the effects of 
inactivated and live probiotic cells on the immune system. It has been shown 
that in tumor necrosis factor (TNF) α induced Caco-2 cells, both live and 
heat-killed GG were effective in downregulating production of interleukin 
(IL)-8, but when there was no pre-existing inflammatory mediator 
stimulation live strain caused an increase in the IL-8 production, whereas 
heat-killed form caused a minimal response (Zhang et al. 2005). An equal 
effectiveness of unviable GG compared to the live strain was demonstrated 
for ultraviolet-inactivated GG using flagellin-induced IL-8 production in 
Caco-2 cells (Lopez et al. 2008). Another in vitro study on live and heat-
inactivated L. acidophilus strains demonstrated that both forms were able to 
inhibit the attachment of pathogenic bacteria to Caco-2 cells in a similar 
manner (Ostad et al. 2009). Furthermore, in infant rats, heat-killed GG 
showed similar results to live GG by decreasing the lipopolysaccharide-
induced proinflammatory mediators and increasing the anti-inflammatory 
mediators (Li et al. 2009). Due to the many recently recovered structural 
components of GG, for instance lipoteichoic acid and pili, it is possible that 
unviable GG, and possibly also other inactivated probiotic strains for which 
data is scarcer, could yield similar health effects compared to live strains. 
However, in terms of terminology it has been highlighted that nonviable 
forms do no fall under the probiotic construct (Hill et al. 2014). 
 
Few studies have also attempted to test the clinical relevance of probiotic 
viability by comparing the effects of viable and unviable strains. An 
inactivated probiotic combination (GG, L. acidophilus La-5 and B. animalis 
subsp. lactis Bb12), included in the trial as a control group, was significantly 
less effective than a combination of the same strains in viable form in the 
prevention of AAD (Wenus et al. 2008). In a trial on atopic symptoms, no 
statistically significant differences were found for live or inactivated GG 
groups compared to the placebo group, but study was discontinued early 
when more GI symptoms appeared in the group receiving the inactivated GG 
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(Kirjavainen et al. 2003). It was hypothesized by the authors that high 
numbers of bacteroides and clostridia might have responded to the 
administered probiotic antagonistically by secreting toxins that induce 
diarrhoea, and only live GG would have been able to restrain the antagonistic 
activity. Consumption of inactivated GG has also led to lower rotavirus 
immune responses compared to a live strain during rotavirus infections 
(Kaila et al. 1995). To conclude based on the clinical evidence, it appears that 
inactivated probiotics might not confer the same health benefits as the live 
strain. However, evidence is still limited and complicated by studies using 
different bacterial inactivation methods, for which details are not always 
reported.  
2.2.5 DOSING 
 
Large variation exists in the dosing of probiotic strains in clinical trials, usual 
levels ranging from 108 to 1013 colony-forming units (cfu) per day. The 
optimal dose is likely to depend on the strain and targeted health effect 
(Aureli et al. 2011). However, within specific strain or combination of strains, 
very few trials have attempted to reveal a dose-effect relationship to specific 
health effects (Bertazzoni et al. 2013). In AAD, a high dose (1010 cfu/d) but 
not low dose (108 cfu/d) of a four-strain probiotic combination (L. 
acidophilus NCFM, L. paracasei Lpc-37, Bifidobacterium (B.) lactis Bi-07, 
B. lactis Bl-04) yielded a statistically significant reduction in AAD incidence 
compared to placebo, and significant linear trend indicated dose-depency 
(Ouwehand et al. 2014). Dose-response was also seen in another trial on 
AAD, using a two-strain probiotic combination of L. acidophilus CL1285 and 
L. casei LBC80R (Gao et al. 2010). In this trial both studied doses were high 
(1013 and 1014 cfu/d). Dose-dependency has also been demonstrated in the 
reduction of the whole gut transit time with the strain B. lactis HN019 at 
daily levels of 1012 and 1013 per day (Waller et al. 2011), and in the softening 
of stools using a combination of two strains (B. animalis ssp. lactis BB-12, L. 
paracasei CRL-431) at daily doses of 108, 109, 1010 or 1011 (Larsen et al. 
2006). On the other hand, two high doses of GG (1010 and 1012 cfu/d) 
decreased the frequency and duration of diarrhoea equally effectively (Basu 
et al. 2009). Thus, based on the available evidence, it can be the strain, the 
health effect in question, or both that are critical for the optimal therapeutic 
dose. Furthermore, synergistic or additional effect accomplished by 
combining two or more strains has been suggested, but evidence for this is 
conflicting, some studies suggesting even a negative outcome (Aureli et al. 
2011). There is also lack of data available on whether probiotics would be 
more effective when consumed in intervals or continuously. 
 
After the consumption of the probiotic, a standard method to demonstrate 
the consumption and evaluate the presence and the amount of the probiotic 
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in the GI tract is the analysis of faecal recovery. Most efficient and specific 
method to measure probiotic presence in faecal or mucosal samples is strain-
specific PCR (Treven 2015). For GG, a quantitative strain-specific assay has 
been developed (Ahlroos and Tynkkynen 2009), which may detect also dead 
and dormant bacteria. Using this method, it has been demonstrated that 
after two week consumption of GG, almost one third of the subjects still 
carried the strain at the end of the three-week follow-up period (Saxelin et al. 
2010).  It has also been shown, using cultivation methods for GG detection, 
that GG can persist in colonic mucosa even after it has disappeared from the 
faecal sample (Alander et al. 1999). Long-term GG recovery has been 
addressed in a study on infants (Gueimonde et al. 2006). In this study, 
mothers received GG supplementation for four weeks before delivery, 
followed by infants receiving GG for the first six months of life directly or via 
breast-feeding mother. GG was recovered from the faecal samples of 58% 
and 78% of infants after the 6-month intervention and from 24% and 26% at 
12 months in the GG group using colony identification and direct PCR, 
respectively. However, GG was also recovered in the faecal samples of 
children in the control group, in 28% and 43% at 6 months and 14% and 20% 
at 12 months by colony identification and direct PCR, respectively. In 
addition, one case study has been reported on faecal GG recovery rates in 
infants born to six women who had consumed GG during late pregnancy 
(Schultz et al. 2004). At 1 and 6 months of age, GG colonization was observed 
in all four delivered vaginally and in one of the two children delivered by 
cesarean section, even though children did not receive any GG 
supplementation after birth. Furthermore, GG was recovered in three 
children at 12 months, and in two children at 24 months. 
2.2.6 SAFETY 
 
European Food Safety Authority (EFSA) has in their qualified presumption 
of safety (QPS) assessments concluded that Lactobacilllus, Bifidobacterium 
and Propionibacterium are safe for consumption (EFSA 2013). However, it 
was pointed out that some case reports on immunocompromised patients 
have emerged relating to the consumption of a strain belonging to 
Bifidobacterium and Lactobacillus genera, especially L. rhamnosus. These 
reports did not change the QPS recommendation of either of the genera, but 
it is recommended that clinical infections including lactobacilli species 
should be closely monitored. Since probiotics are most often administered as 
live strains, their possible infectivity or toxin production has indeed raised 
questions (Sanders et al. 2010). This is largely because probiotics’ safety has 
not been as systematically and rigorously evaluated as drugs’ but has rather 
relied on long and safe history of use.  
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To substantiate the safety of probiotics, retrospective evaluations have been 
conducted. A retrospective study looking at Lactobacillus bacteremia 
incidence in Finland demonstrated that significantly increased GG 
consumption following the introduction of GG to food products in Finland in 
1990 did not lead to rising number of Lactobacillus bacteremia cases 
(Salminen et al. 2002). Further evaluation of the Lactobacillus bacteremia 
cases led to the conclusion that no risk groups of immunocompromised 
patients could be identified (Salminen et al. 2004a). GG has also been used 
in clinical trials in immunocompromised subjects such as low birth weight 
infants (Luoto et al. 2014; Manzoni et al. 2011), and HIV-infected patients 
(Salminen et al. 2004b), without serious adverse events. Reports of three 
individual cases of sepsis with GG-like bacteria have been published on 
patients with short gut syndrome have been reported (De Groote et al. 2005; 
Kunz et al. 2004). However, 12 years’ of experience on the routine use of GG 
in premature infants with low birth weight has been reported, with no cases 
of GG septicemia (Luoto et al. 2010). Recently, an analysis was published 
pooling together adverse event data from six GG trials with the total study 
population of 1909 healthy subjects concluded that GG is safe to consume 
with no rise in adverse events (Tapiovaara et al. 2016b). In patients with 
weakened intestinal barrier function, immune compromised state or central 
venous catheter use, probiotic consumption should in any case be carefully 
considered (Sanders et al. 2010). 
 
2.3 PROBIOTICS IN RESPIRATORY TRACT INFECTIONS 
2.3.1 METHODS TO STUDY CLINICAL EFFECTS OF PROBIOTICS  
 
When the aim is to assess the in vivo effect of a probiotic in RTIs, double-
blinded randomized controlled clinical trials (RCTs) represent the most 
precise approach for determining if a causal relationship exists. Clinical trial 
conduction is guided by the principles of Good Clinical Practise (ICH 1996) 
as well as by the ethical principles laid down in the Declaration of Helsinki 
(World Medical Association 1964), which is regularly updated, most recently 
in 2013 (World Medical Association 2013). Prior to RCT conduction, protocol 
and all study materials are to be evaluated by a local ethical committee. At 
the recruitment phase, subjects need be well informed of all study procedures 
and written informed consent needs to be obtained from all participating 
subjects. Subjects also have the right to withdraw their consent at any stage 
of the trial. In RCTs, the active ingredient, in this case the probiotic, is to be 
compared to a group receiving no probiotic supplementation, serving as the 
control group. To allow the evaluation of the effects of the probiotic strain 
alone, an ideal study product is in every other sense similar to the placebo 
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product, except for the active ingredient. Subjects are placed in the 
intervention groups according to a predetermined randomization list, and 
both subjects as well as all study personnel in contact with the subjects or the 
data should be unaware of who receives probiotic and who placebo, to 
comply with the double blinding. To achieve this, it is also of importance that 
active and control products are unidentifiable from each other. If control 
group receives no product or active and control products can be differed from 
one another, study will be an open trial instead of blinded and of lesser value 
in terms of drawing conclusions especially regarding subjectively evaluated 
effects. In the analysis phase, ideally all randomized subjects should be 
included in the analysis for it to fulfill the criteria of intention-to-treat 
analysis, and thus to ascertain that possible uneven dropout rate in different 
groups does not affect the results.  
 
The approach used for determining the efficacy of a probiotic on the clinical 
outcomes of RTIs has been to study naturally occurring infections. Even 
though RTIs are common, due to the rather modest effects that have been 
demonstrated for most probiotics on the individual level, conducting RCTs 
requires large populations, which can be difficult to recruit, and long 
interventions, even when conducted during the highest RTI incidence, from 
fall to spring. Also possible pathogen verification of the infections can be 
challenging to arrange in large and long studies. Infection-inducing challenge 
studies provide an alternative to long intervention studies, and allow more 
controlled aetiology and follow-up of the course of the RTI. This alternative 
has not been utilized in probiotic trials.  
 
When the ultimate aim is to reduce personal and socio-economic burden of 
RTIs, the experienced symptoms, the patient-reported outcomes, are a key 
endpoint in assessing the effects of probiotics. The Jackson scale is one of the 
most commonly used instruments to define and to evaluate colds and flu in 
adults, including eight symptoms rated as absent, mild, moderate or severe 
(Jackson et al. 1958). The instrument can be used for both self-assessment 
and with clinicians or researchers assistance. Wisconsin Upper Respiratory 
Symptom Survey (WURSS-21 and WURSS-44) is designed for the evaluation 
of the illness-specific quality-of-life outcomes in adult cold sufferers (Barrett 
et al. 2009; Barrett et al. 2002). For measuring colds in children, the 
Canadian Acute Respiratory Illness and Flu (CARIF) scale has been 
developed and validated (Jacobs et al. 2000). Many RCTs use non-validated 
questionnaires for daily symptom follow-up, and varying criteria is applied to 
for instance which number or combination of symptoms is considered an 
RTI case. 
 
Endpoints on the clinical manifestation of RTIs do not, however, provide 
understanding on how the symptom effects are originated. For both 
pathogen antagonism and immunomodulation, adhesion to mucosal surfaces 
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is critical for the probiotic effects (Bermudez-Brito et al. 2012; Collado et al. 
2007), and in respiratory illnesses probiotic ability to persist in the 
respiratory tract is of specific interest. Pathogen presence and load in the 
nasopharynx is a logical endpoint to be measured in clinical trials in order to 
understand if probiotics can reduce the pathogen load or if they are 
specifically effective against certain pathogens.  Task force set by the 
International Life Sciences Institute has concluded that pathogen-specific 
immune responses (specific antibodies and T cell responses after infection) 
and vaccine-specific immune responses (seroconversion, seroprotection, 
specific antibodies and T cells) are useful tools in assessing the possible 
clinical relevance and involvement of the immune system in clinical trials on 
defence against pathogens (Albers et al. 2013). Furthermore, pathogen loads 
were considered clinically relevant endpoint, whereas the majority of ex vivo 
assays (pathogen-specific B and T cell functions, phagocyte function and NK 
cell function) were considered relevant only in limited populations and 
merely indicative of immune function involvement. For instance for acute-
phase response markers (e.g. C-reactive protein, TNF, IL-1 and IL-6), pro- 
and anti-inflammatory mediators, and ex-vivo produced cytokines it was 
concluded that their clinical relevance is unsubstantiated, but they can, 
however, provide mechanistic information and are most useful when 
combined with the follow-up of the symptoms of infection (Albers et al. 
2013). Preclinical data can further support building of the understanding of 
probiotic mechanisms in RTIs. Also factors related to probiotic basic 
properties should not be overseen.  
2.3.2 SYMPTOM IMPACT IN CLINICAL TRIALS 
 
The earliest study addressing probiotics’ ability to reduce RTIs is from 2001 
(Hatakka et al. 2001). Since then, numerous strains have been studied for 
this indication. Results on the effects of the strains with at least two double-
blind RCTs addressing symptom endpoints in RTIs, either as primary or 
secondary endpoints, are reviewed in Tables 2a-i, together with criteria used 
for the endpoints. Only interventions with probiotic identified to the strain 
level and probiotic effect addressed separately rather than in combination 
with other active ingredients were considered in this context. Altogether six 
individual strains and three strain combinations filled these criteria, with 29 
RCTs, all preventive, conducted on them in total. 
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Table 2a. Effects of Lactobacillus rhamnosus GG on symptoms of 
respiratory tract infections in randomized controlled double-blind clinical 
trials. 
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Table 2b. Effects of Lactobacillus casei DN-114001 on symptoms of 
respiratory tract infections in randomized controlled double-blind clinical 
trials.  
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Table 2c. Effects of Bifidobacterium animalis subsp. lactis Bb-12 on 
symptoms of respiratory tract infections in randomized controlled double-
blind clinical trials.  
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Table 2d. Effects of Lactobacillus casei Shirota on symptoms of respiratory 
tract infections in randomized controlled double-blind clinical trials. 
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Table 2e. Effects of Lactobacillus fermentum CECT5716 on symptoms of 
respiratory tract infections in randomized controlled double-blind clinical 
trials.  
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Table 2f. Effects of a combination of Lactobacillus rhamnosus GG, 
Lactobacillus rhamnosus Lc705, Bifidobacterium breve 99, and 
Propionibacterium freudenreichii supsp. shermanii JS on symptoms of 
respiratory tract infections in randomized controlled double-blind clinical 
trials. 
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Table 2g. Effects of a combination of Lactobacillus rhamnosus GG, and 
Bifidobacterium animalis subsp. lactis Bb-12 on symptoms of respiratory 
tract infections in randomized controlled double-blind clinical trials. 
 
 
 
Table 2h. Effects of a combination of Lactobacillus acidophilus NCFM, and 
Bifidobacterium animalis subsp. lactis Bi-07 on symptoms of respiratory 
tract infections in randomized controlled double-blind clinical trials. 
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Table 2i. Effects of Lactobacillus fermentum VRI-003 (PCC) on symptoms 
of respiratory tract infections in randomized controlled double-blind clinical 
trials. 
 
 
 
Based on the trials on infants, both GG (Luoto et al. 2014) and B. animalis 
subsp. lactis Bb-12 (Taipale et al. 2011; Taipale et al. 2016), have shown 
promising effects in reducing RTIs but only in one trial. The ombination of L. 
acidophilus NCFM and B. animalis subsp. lactis Bb-12 has shown some 
efficacy in one study (Rautava et al. 2009), and results for L. fermentum 
CECT5716 are conflicting (Gil-Campos et al. 2012; Maldonado et al. 2012).  
 
In children, GG appears to be able to slightly reduce RTIs (Hojsak et al. 
2010a; Hojsak et al. 2010b; Hatakka et al. 2001). Data from one trial 
supports the efficacy of the combination of L. acidophilus NCFM and B. 
animalis subsp. lactis Bi-07 (Leyer et al. 2009). The combination of GG, L. 
rhamnosus Lc705, B. breve 99, and P. freudenreichii supsp. shermanii JS 
has shown minor effects in one trial in children (Hatakka et al. 2007a). 
Results for L. casei DN-114001 are conflicting (Merenstein et al. 2010; 
Prodeus et al. 2016). B. animalis subsp. lactis Bb-12 has not been able to 
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reduce RTIs in children (Weizman et al. 2005; Hojsak et al. 2015a; Hojsak et 
al. 2015b).  
 
In adult subjects, L. casei Shirota has shown most promise in reducing 
respiratory illness (Gleeson et al. 2011; Shida et al. 2015), L. fermentum 
CECT5716 (Olivares et al. 2007) and combination of GG and B. animalis 
subsp. lactis Bb-12 (Smith et al. 2013) have shown minor effects in single 
trials, whereas GG (Kekkonen et al. 2007), L. casei DN-114001 (Tiollier et al. 
2007; Guillemard et al. 2010a), the combination of L. acidophilus NCFM and 
B. animalis subsp. lactis Bi-07 (West et al. 2014) or L. fermentum VRI-003 
(Cox et al. 2010; West et al. 2011) have not been effective in adults.  
 
Trials on the elderly have shown very minor to no effects with any probiotic. 
Both L. casei DN-114001 (Guillemard et al. 2010b) and the combination of 
GG, L. rhamnosus Lc705, B. breve 99, and P. freudenreichii supsp. 
shermanii JS (Hatakka) have shown minor positive effects in one trial. L. 
casei Shirota showed minor beneficial effect in one trial (Fujita et al. 2013) 
but was ineffective in the other (Van Puyenbroeck et al. 2012).  
 
Out of the studies with only one RCT reported addressing RTIs, no effect was 
found for L. casei CRL431 (Agustina et al. 2012), L. reuteri DSM17938 
(Agustina et al. 2012), L. rhamnosus HN001 (Cáceres et al. 2010), L. 
rhamnosus T cell-1 (Lin et al. 2009), L. reuteri SD2112 (Weizman et al. 
2005), the combination of GG, L. acidophilus LA-5, and B. animalis subsp. 
lactis Bb-12 (Kloster Smerud et al. 2008) and the combination of GG and B. 
animalis subsp. lactis Bb-12 (Kalima et al. 2016). The following strains, with 
just one RCT conducted to date, gave at least some indication of potential in 
reducing respiratory symptoms: L reuteri DSM 17938 (Gutierrez-Castrellon 
et al. 2014), L. acidophilus NCFM (Leyer et al. 2009), L. delbrueckii subsp. 
bulgaricus OLL1073R-1 (Makino et al. 2010), B. animalis subsp. lactis Bl-04 
(West et al. 2014), L. reuteri protectis (Tubelius et al. 2005) L. casei 431 
(Jespersen et al. 2015), and the combination of L. gasseri PA 16/8, B. 
longum SP 07/3, B. Bifidum MF 20/5 (de Vrese et al. 2006; de Vrese et al. 
2005; Winkler et al. 2005), as well as the combination of  L. plantarum 
HEAL-9 and L. paracasei 8700:2 (Berggren et al. 2011). 
 
To conclude, data on the ability of specific probiotic strains to reduce RTIs is 
still limited as there is lack of trials confirming the findings of earlier trials 
with the same strain in similar populations and settings. It should also be 
noted that variety of RTI endpoints and criteria for these endpoints have 
been used in the studies, which makes it challenging to compare findings 
between trials. Furthermore, lack of studies comparing the effects of the 
most potential probiotics (strains for which efficacy is clinically 
demonstrated in earlier studies) is apparent. Comparative trials in RTIs have 
to date been conducted for comparing potential probiotic candidates to 
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strains with some data on clinical effects (Weizman et al. 2005; West et al. 
2014). No dose-response studies assessing probiotic effects on RTIs have 
been conducted with any strain. Overall the research process of probiotics in 
RTIs, regarding clinical effect, effective dose, product matrix, mechanisms as 
well as safety has lacked systematicity that is present for instance in the 
phase process of pharmaceutical research. 
2.3.3 RESPIRATORY PATHOGENS  
 
Respiratory pathogen findings in clinical trials 
Probiotic strains can possess properties able to inhibit the colonization of 
pathogenic micro-organisms (Bermudez-Brito et al. 2012). Probiotic effects 
on the upper respiratory tract or middle ear pathogen presence have been 
reported from six double-blind RCTs addressing the effects of two individual 
probiotic strains and one combinations of probiotic strains (Table 3). The 
results demonstrate that only GG and the combination of L. rhamnosus GG, 
L. rhamnosus Lc705, B. breve 99, P. freudenreichii subsp. shermanii JS have 
reached statistical significance between probiotic and control groups in 
reducing the presence of pathogens. RV-induced infections were fewer in the 
symptomatic infants who had received GG supplementation during the first 
two months of life compared to the control group (Luoto et al. 2014). The GG 
containing combination has reduced two of all the studied pathogens, M. 
catarrhalis and HboV, in asymptomatic otitis-prone children (Hatakka et al. 
2007a; Lehtoranta et al. 2012). No effect has been demonstrated in 
respiratory pathogen reduction for any other probiotic strains or pathogen, 
but data is still limited for drawing of the final conclusions. In addition to the 
double-blind RCTs, an open prospective trial found that nasal colonisation of 
potentially pathogenic bacteria decreased slightly after the consumption of 
GG, Bifidobacterium B420 (species not specified), L. acidophilus 145 and S. 
thermophilus (strain not specified) compared to placebo in healthy adults, 
but there were no significant differences between the probiotic and control 
groups (Glück and Gebbers, 2003).  
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Table 3. Upper respiratory tract and middle ear pathogens in double-blind 
randomized controlled clinical trials on probiotics. 
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Effect on pathogens in preclinical experiments 
Preclinical trials on lactobacilli and bifidobacteria strains have demonstrated 
that probiotics can have antagonistic activity towards e.g. Escherichia coli, 
Salmonella, Helicobacter pylori, Listeria monocytogenes and rotavirus. 
Probiotics can inhibit pathogen adherence by non-specifically covering 
receptor sites, as shown for instance for GG with E. coli and Salmonella 
subsp. (Lee and Puong 2002), or by competing for the same receptors. GG 
has also the ability to induce epithelial expression of mucin genes, which can 
inhibit adherence of E. coli to epithelial cells in vitro (Mack et al. 2003; Mack 
et al. 1999). Mucins on mucosal surfaces can potentially protect epithelial 
cells from pathogens either via supporting the physico-chemical barrier, or 
by binding to pathogenic bacteria or virus. For bacterial pathogens, 
combination of GG, L. rhamnosus Lc705, P. freudenreichii ssp. shermanii JS 
and B. breve 99 or B. lactis Bb12 was able to inhibit and to displace adhered 
pathogens by competitive exclusion (Collado et al. 2006), and same was 
shown for several individual commercial strains, such as GG, L. rhamnosus 
Lc705, L. casei Shirota, L. acidophilus NCFM, B. lactis Bb12, B. breve 99, 
and P. freudenreichii subsp. shermanii JS (Collado et al. 2007). The results 
highlighted that as strains differed in their ability to inhibit and exclude 
specific pathogens, case-by-case assessment would be beneficial when 
selecting probiotic to target specific pathogens. No similar comparative 
experiments have been reported for common RTI pathogens.  
 
Probiotics may also produce antimicrobial substances, such as organic acids 
and antibacterial peptides, that can inhibit the growth of pathogens 
(Bermudez-Brito et al. 2012). It is also possible that probiotic strains release 
defensins, small peptides or proteins that are active against bacteria and 
viruses, from epithelial cells (Bermudez-Brito et al. 2012). Only a few in vitro 
trials have attempted to shed light to possible antagonistic activities of 
probiotics against respiratory viruses. Several Bifidobacterium and 
Lactobacillus strains have been shown to bind directly to a virus and thus 
inhibit its attachment to host cell in an eukaryotic cell culture mode (Botić et 
al. 2007). The same study demonstrated that tested probiotic strains secreted 
metabolic products that had direct antiviral effect. Studies on macrophages 
from animal cell lines have indicated that production of nitric oxide could 
also have a role in probiotics’ possible protective effects in RTIs (Ivec et al. 
2007; Korhonen et al. 2001; Pipenbaher et al. 2009; Yeo et al. 2014). No data 
on such antagonistic effects is available for strains with clinical data in RTIs.  
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2.3.4 IMMUNOMODULATION 
 
Immunomodulation in clinical trials 
Few of the clinical probiotic trials on RTIs have attempted to shed light to the 
changes in immunological markers during the intervention. In healthy shift 
workers, in a study with no statistically significant effects in RTIs, two month 
consumption of L. casei DN-114001 did not affect hemogram parameters, C-
reactive protein, NK cell count or activity, oxidative burst, or cytokine 
production analysed from blood samples (Guillemard et al. 2010a). However, 
when samples were taken during infections (both respiratory and GI 
infections combined), leukocytes, neutrophils, NK cell counts, and NK cell 
activity increased more, within the normal range, in the probiotic group 
compared to the control group. For leucocytes, the change was most 
emphasized during rhinopharyngitis, for NK cell count during all RTIs, 
rhinopharyngitis or sore throat, and for NK cell activity, during cases of sore 
throat. When the same strain was consumed by free-living elderly and a 
decrease in the duration of upper RTIs was observed, no difference was 
detected between the groups in the same biological and immunological 
parameters, but comparison of samples taken during an infection could not 
be done due to an insufficient number of infections (Guillemard et al. 
2010b). A 3-month trial on L. casei Shirota on middle-aged office workers, in 
which probiotic reduced the infections of the upper respiratory tract, showed 
that after 1.5 months of probiotic consumption, NK cell activity was higher in 
the probiotic group compared to the control group, but difference was not 
observed at the end of the intervention (Shida et al. 2015). There were no 
differences in the salivary IgA or cortisol levels between the groups on either 
of the time points.  
 
In heavily training adults consuming L. fermentum PCC® for three months 
was overall ineffective in reducing RTIs, but acute exercise-induced changes 
in anti-inflammatory (IL-1ra, IL-10), immuno-regulatory (IL-6) and pro-
inflammatory (IL-8, granulocyte macrophage-colony stimulating factor, IFN-
γ, TNF-α) cytokines were reduced in the probiotic group compared to the 
control group (West et al. 2011). However, no substantial differences were 
observed between the groups in the resting cytokine concentrations or in the 
mucosal immune measures of lactoferrin, lysozyme or IgA from pre- to post-
supplementation, and no clear relationship between the reduced exercise-
induced cytokine levels and symptoms could be identified. In another study 
on the same strain and in similar study population of athletes, where also 
symptom reduction was observed in the active group, probiotic consumption 
had no effect on salivary IgA or IgA1 concentrations compared to control 
group, and no statistically significant differences were observed in the 
measured cytokine responses (IL-4, IL-12, IFN-γ) even though it appeared 
that probiotic supplementation slightly attenuated the reduction in IFN-γ 
and IL-12 that was more apparent in the control group (Cox et al. 2010). In a 
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4-month study on L. casei Shirota on athletes, where RTI symptom and 
episode reductions were observed, saliva IgA concentrations were higher and 
monocyte counts slightly lower in the group receiving the probiotic compared 
to the control group after two and three months of supplementation (Gleeson 
et al. 2011). However, no differences were observed between the groups in 
the plasma concentrations of IgA and IgM, in other blood leukocyte counts 
than the monocytes, in lymphocyte subsets or in the stimulated whole-blood 
culture cytokine production. Based on this and the symptom findings, the 
authors concluded that probiotics ability to maintain saliva IgA levels could 
have a role in the reduction of the infection episodes of the upper respiratory 
tract observed in the trial. When hormonal as well as mucosal and cellular 
immune parameters were measured in commando training participants 
receiving L. casei DN-114001, no difference was observed in the RTI 
endpoints in the cell counts of leukocytes or lymphocytes, but a decrease in 
dehydroepiandrosterone sulfate, an immunostimulatory hormone, was 
observed in the probiotic group (Tiollier et al. 2007). 
 
Few influenza vaccination trials have been performed in an attempt to reveal 
the possible capacity of probiotic consumption to modify humoral immune 
responses in human subjects. A clinical trial on GG demonstrated that the 
strain, given together with influenza vaccine, could enhance the 
immunogenicity of IFV H3N2 strain, but greater seroprotection was not 
observed for H1N1 and B strains (Davidson et al. 2011). Two clinical trials on 
L. casei DN-114 001 show that probiotic consumption increased 
seroconversion for IFV B virus, but statistically significant difference was not 
observed for H1N1 or H3N2 (Boge et al. 2009). B. animalis ssp. lactis Bb12 
consumption led to an elevated vaccine-specific IgG antibodies in plasma 
and secretory IgA in saliva compared to control group in an influenza vaccine 
trial, but no difference was seen in plasma cytokines or innate immune 
parameters (Rizzardini et al. 2012). A four week consumption of L. 
fermentum CECT5716, and influenza vaccination given after two weeks of 
intervention, led to significantly higher antigen-specific IgA levels in the 
probiotic group at the end of the intervention, but no significant differences 
were detected between the groups in the antigen-spesific IgG or IgM 
(Olivares et al. 2007). In addition to changes in virus-neutralizing antibodies, 
increased TNF-α levels were observed in the probiotic group compared to the 
control group. In the elderly, the consumption of L. casei Shirota for three 
weeks before and five months following an influenza vaccination resulted in 
similar anti-influenza antibody titers in the probiotic and control groups 
when measured by the hemagglutination inhibition of A/H3N2 (Van 
Puyenbroeck et al. 2012). The humoral response to the vaccine, analysed by 
pre- and postvaccination geometric mean titres and rates of seroconversion 
and seroprotection, was also similar in both groups.  
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Immunomodulation in preclinical experiments 
Results from numerous in vitro and animal experiments indicate that 
probiotics interact with mucosal immune cells and epithelial cells lining the 
mucosa, and via these cells modulate the mucosal immune system (Wells 
2011). An important route for immunomodulation is via binding to pattern 
recognition receptors (PRR), such as Toll-like receptors, which can recognize 
microbe-associated molecular patterns (MAMPs), which then induce the 
production of innate effectors such as cytokines and chemokines. Balancing 
the production of the anti- and proinflammaroty cytokines could be a key 
factor behind probiotics’ beneficial effects also in RTIs. Based on preclinical 
data, probiotics might also be able to affect epithelial signalling, T regulatory 
cells in the mucosa, the effector subsets of T cells, epithelial-associated DCs 
and macrophages, as well as humoral immunity, but little is still know about 
most of these interactions (Wells 2011). GG for example has demonstrated 
ability to modulate the cytokine expression patterns in human DCs and 
macrophages in several in vitro trials (Lehtoranta et al. 2012a; Miettinen et 
al. 2000; Veckman et al. 2004; Veckman et al. 2003).  
 
In human macrophages, L. rhamnosus Lc705 induced IFN-dependent gene 
activation, correlating with the production of viral proteins and lower IFV A 
virus replication (Miettinen et al. 2012). A study on murine DCs 
demonstrated that L. acidophilus NCFM is able to induce the expression of 
viral defense genes (IFN-β, IL-12, IL-10) (Weiss et al. 2011). Several markers 
of cell-mediated immunity have been connected to infection endpoints in 
studies on animal models. Orally given L. casei Shirota has been shown to 
protect neonatal and infant mice against IFV infection, with increased 
pulmonary NK cell activity and IL-12 production in lymph node cells 
observed (Yasui et al. 2004). The same strain has been administered 
intranasally to mice in two studies, both of which demonstrated lowered IFV 
titers and increased mice survival, with increased IL-12, IFN-γ, TNF-α in 
mediastinal lymph node cells in the first study (Hori et al. 2001), and with 
increased NK activity of splenocytes and lung cells as well as induction of 
IFN-γ and TNF-α in nasal lymphocytes in the second study (Hori et al. 
2002). Intranasally administered GG protected mice from IFV infection, with 
up-regulation of lung NK cell activity (Harata et al. 2010).  
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3 AIMS OF THE STUDY 
The aim of this work was to study the clinical outcomes of Lactobacillus 
rhamnosus GG consumption in respiratory tract infections in healthy 
children and adults, as well as aspects that were hypothesized to have a role 
behind the clinical effects of the probiotic. 
  
The specific aims were: 
1. To investigate whether the intake of L. rhamnosus GG, as a single 
strain or as a part of a multispecies combination, would lead to the 
recovery of the probiotic in tonsil tissue in young adults (I) 
2. To study the effect of long-term consumption of L. rhamnosus GG on 
respiratory tract infections in children attending day care (II) 
3. To assess if a long-term consumption of L. rhamnosus GG can reduce 
the occurrence of common respiratory viruses in the nasopharynx in 
symptomatic children attending day care centers (III) 
4. To assess the potential of human rhinovirus challenge model in 
probiotic trials and, using the model, to evaluate the effect of live and 
inactivated L. rhamnosus GG on prevention and symptom impact 
during rhinovirus infection in adults in pilot-scale (IV) 
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4 MATERIALS AND METHODS 
4.1 SUBJECTS AND STUDY DESIGNS 
Altogether three clinical trials were conducted, and one study was performed 
on a subgroup of one of the intervention studies. All three studies were 
double-blinded randomized, and placebo-controlled clinical trials. One of the 
studies had two parallel groups (control and live GG, study II) and two of the 
studies had three parallel groups (control, GG as single live strain and as the 
third group either inactivated GG in study IV or live GG together with three 
other live strains, L. rhamnosus Lc705, B. breve Bb-12 and P. freudenreichii 
supsp. shermanii JS in study I). Two of the studies, II and IV, were designed 
primarily for RTI follow-up. Study II followed naturally occurring infections 
in children attending day care during one infection season between 
September and May, and collected daily parent-reported respiratory 
symptom data as well as data from physician visits due to infections. Study 
IV utilized an experimental RV challenge model, in which subjects were 
inoculated mid-intervention with RV immunotype 39 (IND 12934) from an 
FDA-approved pool, administered in two inocula, 250 μl per nostril given 5-
15 min apart. In this pilot study both subject and researcher recorded 
symptom data was collected, as well as several samples for the evaluation of 
the infection rates and endpoints related to it. Studies I and III were 
designed to address aspects that were hypothesized to have a role behind the 
symptom effects in RTIs, the recovery of GG in the upper respiratory tract in 
study I and the nasopharyngeal presence of respiratory viruses in study III. 
Study IV was also designed to assess the role of the viability of GG. Overview 
of study designs is presented in Figure 2 and of study populations in Table 4.  
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Figure 2. Overview of study designs of the randomized controlled trials. 
Abbreviations: GG, Lactobacillus rhamnosus GG; wk, week. 
 
 
Table 4. Overview of study populations. 
 
 
 
In study II, the number of days with respiratory symptoms in a similar 
previous trial (Hatakka et al. 2001) was used to calculate the required sample 
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size, and 20% reduction in the symptom days was estimated to occur in the 
group receiving GG. The previous study was not directly used as the basis of a 
power calculation, as there were differences in the setup potentially affecting 
the outcome, such as the provision of milks also during absences from day 
care (compared to comsumption only when in day care in the previous trial) 
and narrower age group. Thus, the total sample size of about 600 children 
(300 in each group) was estimated to be needed in order to detect a 20% 
difference between the study groups with a power of 85% and at a 
significance level of 0.05. Studies I and IV were pilot-scale trials, and in both 
studies it was estimated that sample size of 60 subjects (20 in each of the 
three groups) would give enough indication on if the issue is worth 
addressing in further larger trials with enough power for detecting a 
difference between the groups.  
 
Subjects were recruited to the studies from patients on the waiting list for 
tonsillectomy (study I), via information delivered through day care centres 
participating in the study in Kainuu and Oulu regions (study II), and via 
advertisements in the local newspapers and e-mail distribution lists (study 
IV). Criteria for subject participation are presented in Table 5. In all trials, 
subjects were not allowed to participate in any other clinical trials during the 
present study, and they had to agree to follow the protocol. Recruitment of 
subjects for study I was done between October 2007 and November 2008. 
Study II was carried between September 2009 and May 2010, and study IV 
between August 2010 and November 2010.  
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Table 5. Inclusion and exclusion criteria in the trials. 
 
 
4.2 PROBIOTIC ADMINISTRATION AND DOSING 
Subjects in all trials were randomly allocated to probiotic or control group 
according to a computer-generated randomization lists prepared by a 
statistician. In study I, randomization was stratified according to age and 
gender. Details of study products are presented in Table 6. In all trials, all 
groups consumed the same carrier product according to the same routine, 
the only difference between the groups being the probiotic supplementation 
of the active groups’ products according to the dosing specified in Table 6. In 
studies I and IV, products were only marked with study numbers and were 
otherwise blank. In study II, control and active products were packed in 
different coloured cartons, due to practical reasons, but consumed products 
had the same taste and appearance. In studies I and IV product doses were 
fixed, but in study II children consumed the study milks on three daily meals, 
without fixed amount. Prior to study it was estimated that children would 
consume on average 4,5 dl of milk per day (3 x 1,5 dl). 
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Table 6. Carrier products and probiotic supplementation in the active 
groups. 
 
 
4.3 DATA COLLECTION 
All data collection, including study product consumption follow-up, health 
data and collection of biological samples, is summarized in Table 7.  
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Table 7. Collection of biological samples and information on health and 
study product consumption in the clinical trials. 
 
 
 
During all interventions, the most important source of health data was 
subject-recorded symptoms, or in the case of children parent-recorded, and 
the symptom data was collected by means of paper study diaries (Table 7). In 
study II, the study diary used an unvalidated questionnaire of respiratory 
symptom presence, without the classification of symptom severity, which was 
based on a questionnaire used in the previous trial with a similar set-up 
(Hatakka et al. 2001). The parent-recorded data was supplemented by 
physician-recorded data from physician visits due to symptoms of respiratory 
or GI infection. To follow the normal procedures of when a child gets an 
infection as closely as possible, families were instructed to visit the study 
physician only in the cases in which they would normally take the child to a 
doctor due to symptoms of respiratory or GI infection. Study physicians 
worked at private health centres and were familiarized with the study 
protocol including filling out a structured questionnaire with detailed 
information of the visit, and collection and storage of an NPS sample. If 
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subject was taken to a physician who was not involved in the study, parents 
were requested to ask the physician to write information of the visit to the 
study diary. In study IV, in addition to subjects filling in study diaries at 
home in the evenings throughout the study, data on the same endpoints was 
recorded by a study nurse at the study site in the morning prior to the virus 
inoculation and on five mornings following this. Follow-up of study product 
consumption was done via study diaries, day care centre personnel and study 
site personnel.  
 
Faecal, tonsil, blood, NPS and nasal lavage samples were collected during the 
trials (Table 7). Faecal samples were collected at home in all trials, and 
subjects or their parents were advised to deliver samples immediately to a 
study centre. In study II, if immediate delivery was not possible, instructions 
were to store the samples in a fridge for up to two hours or in a freezer for up 
to two days. In study I, two tonsils collected during the tonsillectomy from 
each subject were divided into ten parts, and frozen in liquid N2. Venous 
blood samples were drawn four hours after the operation in study I, and in 
study IV, all serum samples were collected in fasting conditions. In study III, 
NPS samples were collected by a flocked-tip nylon swab, which was inserted 
into the nasopharynx through the nose. After collection the swab was placed 
immediately into a vial containing 3 mL of universal transport medium. To 
collect the nasal lavage specimens in study IV, 5 mL of 0.9% sterile saline was 
installed into each nostril with subject sitting head tilted back. Head was bent 
forward when saline started running towards the oropharynx, to allow the 
collection of lavage fluid to a cup. All samples were stored at -70°C until 
analysis. 
4.4 CRITERIA FOR SYMPTOM-BASED ENDPOINTS  
The criteria and data sources for endpoints based on respiratory symptom 
data collected in studies II and IV are presented in Table 8. In study IV, 
Jackson scale was used to score symptom presence and severity. The used 
method of symptom scoring and of diagnosing illness is based on a 
modification (Gwaltney 1992; Gwaltney et al. 1980) of a previously described 
method (Jackson et al. 1958). 
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Table 8. Criteria and data sources for endpoints on clinical manifestations 
of respiratory tract infections. 
 
 
4.5 BACTERIAL, VIROLOGICAL AND IMMUNOLOGICAL 
ANALYSES 
Real-time quantitative PCR of GG in faecal samples (I, II, IV) 
Strain-specific real-time quantitative PCR assay was used for faecal samples 
to quantify GG according to a published method (Ahlroos and Tynkkynen 
2009). Samples were analysed from all subjects who provided a sample both 
before and at the end of the interventions. The frozen samples were thawed, 
suspended in the ratio 1:10 with 50mM-EDTA in blender bags and 
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homogenised with a stomacher blender (Seward, Worthing, UK) for two 
minutes. The suspension was then diluted in the ratio 1:10 using 50 mM-
EDTA, reaching final faecal dilution of 1:100. Following this, 1 mL of the 
dilution was centrifuged at 14 000 g for two minutes. Cells were collected 
and resuspended in 480 mL of 50mM-EDTA, and 100 mL of 50 mg/mL 
lysozyme (Amresco, Solon, USA) and 20ml of 50 U/mL (0,08 kat/l) 
mutanolysine were added (Sigma). The mixture was incubated at 37°C for 
one hour and then centrifuged for two minutes at 14 000 g. The cell pellet 
was extracted according to the manufacturer’s instructions with Wizard® 
Genomic DNA Purification Kit (Promega, Madison, USA), and purified DNA 
suspended in 200 mL of Tris–EDTA buffer.  Genomic DNA from pure 
culture GG (cells from 1 mL of the culture collected and the DNA isolated 
using the same method) was used as a standard in quantitative PCR. The 
strain-specific detection limit for GG on the log10 scale was 5.18 log10 genome 
copies/g in study I, and 5.5 log10 genome copies/g in studies II and IV. 
 
Real-time PCR of GG in tonsil samples (I) 
Tonsil aliquots of approximately 0.5 g were immersed in 480 mL of 50M-
EDTA followed by cell lysis, according to the assay described for faecal 
samples. The samples were repurified with the Wizard® Genomic DNA 
Purification Kit (Promega) before PCR due to impurities caused by the blood 
contained in the samples. The DNA dilutions were made to 100 mg/mL, of 
which 50 ng was used to detect GG in real-time PCR. Because the tonsil 
samples were different in terms of the amount of tonsil surface and thus 
differences in the potential adhesion area of GG in each sample, quantitative 
analyses were not possible to perform.  
 
Viral nucleic acid extraction and PCR assays for respiratory viruses in NPS 
samples (III) 
Fourteen respiratory viruses were analysed from the NPS samples: RV, EV, 
AdV, RSV, IFV A (H1N1)pdm09, IFV A(H3N2), IFV B, PIV1–3, and HBoV1–
4. BioSprint 96 One For All Vet-kit (Qiagen, Hilden City, Germany) was used 
to purify viral nucleic acids from 100 mL of NPS samples with an automated 
KingFisher ml purification system (Thermo Fisher Scientific, Vantaa, 
Finland). Viral RNA and DNA samples were tested using real-time PCR 
methods for RV and EV (based on TaqMan chemistry were), multiplex and 
singleplex real-time quantitative PCR assays for HBoV1–4 (Allander et al. 
2007; Kantola et al. 2010), real-time or reverse transcriptase PCRs for AdV, 
IFV A and B, RSV, and PIV1–3 (Akinloye et al. 2011), and RT-PCR for the 
specific detection of IFV A(H1N1) pdm09 (Rönkkö et al. 2011). For HboV, 
samples with over 10 000 copies/mL were considered to be of high viral load, 
and those positive samples were included in the analyses. 
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Rhinovirus shedding in nasal lavage specimens by isolation in cell cultures 
(IV) 
An aliquot of nasal lavage fluid was inoculated into two tubes of human 
embryonic lung fibroblast cells (MRC-5 or WI38). Samples were incubated in 
roller drums at 33 °C for 14 days, and identification of rhinovirus was done 
based on the development of a cytopathic effect (Couch 1990). 
 
Serum neutralizing antibody response (IV) 
Neutralising antibody response was tested from the sera collected before the 
inoculation and at the end of the study by a standard method (Hamparia 
1979). A four-fold increase in antibody titer between the paired sera was 
considered a serologic response to the challenge virus.  
 
Rhinovirus infection (IV) 
If subject had at least one positive rhinovirus culture or at least a four-fold 
rise in antibody to the challenge virus, the subject was considered infected. 
4.6  SAFETY  
Adverse events during the trials were followed, recorded and evaluated 
throughout the whole interventions for continuous monitoring of safety. 
Adverse events were followed up by means of study diaries in trials I and II. 
In study IV, subjects visited the study site and were questioned on possible 
adverse events by study personnel daily during the intervention. In studies II 
and IV detailed adverse event forms were filled out for all adverse events.  
4.7 STATISTICAL ANALYSES 
The statistical analyses in studies were performed using STATA (StataCorp, 
Texas, USA) or SPSS (SPSS Inc, Chicago, IL, USA) software. Data are 
presented as counts and percentages, medians and interquartile ranges 
(IQR), or means and standard deviations (SD) or 95% confidence intervals 
(CIs).  
 
In study I, Fisher–Freeman–Halton test was used for the comparisons 
between the groups for dichotomous and ordinal level outcomes, and  
Kruskal–Wallis test for continuous variables, and Dwass–Steel–Critchlow–
Flinger test for pairwise comparisons. Kappa statistic (κ) and Jaccard 
similarity index (Chamberlain's positive agreement) were applied for the 
comparison of the tonsil and faecal recovery of GG. In this analysis, the level 
of agreement is considered poor with κ<0.20, fair with κ = 0.21 to 0.40, 
moderate with κ=0.41 to 0.60, substantial with κ=0.61 to 0.80, and very 
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good with κ>0.80.  The 95% CI for Kappa statistic were obtained using bias 
correcting bootstrapping. In Jaccard index, the proportion of positive 
agreement (both faecal and tonsil sample are positive) is divided by all 
positive findings in either of the samples. Jackknife equation was used to 
calculate the 95% CIs for Jaccard index. 
 
In study II, chi square test was used for the comparison of dichotomous 
outcomes between groups and Poisson regression models were used for 
analysis on the number of episodes and symptom days per month, incidence 
rate ratios (IRRs) and P-values between the groups. 
 
In study III, chi-square test was used for categorical variables and the 
independent samples t-test, permutation test, or Wilcoxon rank sum test was 
used for a continuous variable in the demographic characteristics between 
the study groups. Poisson regression model was used for analysis of the 
number of symptom days per month (incidence rates) and P-value between 
groups concerning this endpoint. Permutation type probit regressions were 
used for the testing of differences between the two study groups in viral 
findings, with standard error adjusted for the number of children (194 
clusters). The 95% CI for the number of symptoms were obtained by bias-
corrected bootstrapping (2000 replications). 
 
In study IV, chi square test, bootstrap type analysis of variance and Kruskall-
Wallis test were used for the between-group comparisons depending on the 
distribution of the outcome. Generalising estimating equation models with 
exchangeable correlation structure and appropriate contrasts were used for 
the analysis of the repeated measurements. Data from different time points 
was combined by calculating the area under the curve (AUC) divided by the 
total time in question. No adjustment was made for multiple testing, because 
this information can be obtained, e.g. after Bonferroni, by multiplying the 
actual P-value by the number of comparisons made. 
4.8 ETHICS 
All studies were conducted according to the guidelines laid down in the 
Declaration of Helsinki (World Medical Association 1964), the updates that 
have followed, latest being from 2013 (World Medical Association 2013) and 
following good clinical practise. All procedures involving human subjects 
were approved by the local ethics committees (Ethics Committee of Helsinki 
University Central Hospital in study I, Ethics Committee of Joint Authority 
of Kainuu Region in study II/III, and Human Investigation Committee at 
University of Virginia in study IV). Subjects for the studies were volunteers 
who themselves or their parents gave a written informed consent to 
participate in the study.   
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5 RESULTS 
5.1 BASELINE CHARACTERISTICS (I-IV) 
In study I, the mean age of subjects was 24.5 years (24.4, 25.5 and 23.9 years 
in GG, multispecies and control groups, respectively), and 68% of the 
subjects were female. 21 % of the subjects smoked at least weekly, and half of 
the smokers were in the control group. Subjects did not consume any regular 
medications that would be of relevance regarding the study endpoints, nor 
had they any diagnosed diseases.  
 
In study II, the mean age of subjects was four years, and 47% of the subjects 
were girls in both groups. The mean number of siblings was 1.3 in both 
groups. The median number of months in day care was 24 and 20 months in 
the GG and control groups, respectively. Median duration of exclusive 
breastfeeding was four months and partial breastfeeding seven months in the 
GG group. The corresponding durations were three and eight months in the 
control group. 10% of children in the GG group and 6% in the control group 
had been diagnosed by a physician with atopic eczema earlier in life, but were 
no longer suffering from symptoms, where as proportions for diagnosed and 
still symptomatic children were 8% and 18% in the GG and control groups, 
respectively. Numbers of other allergic diseases and asthma were low, and 
they were similarly distributed between the groups. There was more 
adenoidectomies performed to children in the GG group (14%) compared to 
those in the control group (10%). Health of children during the past year 
preceding the trial was similar in both groups.  
 
Study III presented a subpopulation of study II, including children with at 
least one visit to a study physician with NPS sample collected. There were no 
significant differences in the baseline characteristics between the GG and 
control groups in this subpopulation. Compared to the children in study II, 
the children in study III were slightly younger with mean age of 3.7 (SD 1.3) 
and 3.8 (SD 1.4) in the GG and control groups, respectively, and had also 
spend less time in day care at the start of the intervention (median duration 
18 months in both groups). 
 
In study IV, the mean age of subjects was 22.5 years (24.3, 23.3 and 22.5 
years in live GG, inactivated GG and control groups, respectively), and 13% of 
the subjects were female.   
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5.2 PROBIOTIC RECOVERY IN FAECAL AND TONSIL 
SAMPLES (I, II, IV)  
Recovery of GG in faecal samples (I, II, IV, including unpublished results) 
Summary of received faecal samples and recovery of GG is presented in Table 
9. Both samples (before and at the end of the intervention) were received 
from 43% of the subjects in study II, to up to 97% of the subjects in study IV. 
At the start of the intervention, GG was found in 63% (study I, with a one 
week run-in period), in 34% (study II, with a run-in period of 2-3 weeks), and 
in 12% (study IV, with a run-in period of three weeks) of analysed faecal 
samples. The number of samples with GG above the detection limit increased 
from the start to the end of the intervention in all groups receiving GG. GG 
concentration also increased in the positive samples in all groups receiving 
GG except for one group (study I, group receiving GG as part of a 
multispecies combination). Correspondingly, in the control groups the GG 
concentration decreased, except for study I.  
 
In an ideal case in terms of evaluating the effect of the probiotic intervention, 
GG would be below the detection limit before the intervention in all subjects’ 
fecal samples in all groups, and above the detection limit at the end of the 
intervention in all of the subjects in the GG groups and below the detection 
limit in the control group. The subjects who filled these criteria were termed 
as the “completed cases”, and they represented one third of the subjects in 
study I, 59% in study II and 86% in study IV. In study II, the baseline 
characteristics of this subgroup were similar for children in the GG and 
control groups, but the age of the children differentiated this subgroup from 
the whole study population, as the children in this subgroup were older than 
the rest of the children in this study (mean 4.3 [SD 1.3] vs. 3.9 [SD 1.3], 
P=0.031).  
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Table 9. Summary of analysed faecal samples and faecal recovery of 
Lactobacillus rhamnosus GG in these samples analysed by strain-specific 
real-time quantitative PCR method (detection limits 5.2, 5.5 and 5.5 log10 
genome copies/g for studies I, II and IV, respectively). 
 
 
Recovery of GG in tonsil samples (I) and its association with faecal recovery 
of GG (III) 
In the tonsil samples, GG was recovered from 40% of the samples in the GG 
group, 42% in the multispecies group and 30% in the control group (P-value 
between the groups 0.79). Out of the 51 subjects who provided both tonsil 
and faecal samples at the end of the intervention, 80% (41 subjects) 
demonstrated a positive faecal recovery of GG, and of these 41% also 
demonstrated a positive recovery of GG in the tonsil tissue. Out of the 10 
subjects with negative recovery of GG in faeces, none had GG recovered from 
the tonsil sample. Out of the six subjects in the control group, from whom GG 
was recovered in the tonsil tissue, GG was also found in the faecal sample in 
all subjects with the end of the intervention sample available (one of these six 
subjects failed to provide the sample). Furthermore, four of the six subjects 
had GG recovered from the faecal sample already at the start of the 
intervention. The observed agreement between faecal and tonsil GG recovery 
was 53%, with Jaccard index of 0.41 (95% CI 0.26, 0.57), and the κ-statistic 
of 0.22 (95% CI 0.10, 0.40). 
5.3 EFFECT OF PROBIOTIC ON SYMPTOMS OF 
RESPIRATORY TRACT INFECTIONS (II-IV) 
Results on clinical manifestations of RTIs in studies II and IV are presented 
in Table 10. No statistically significant differences were observed in either of 
the studies on the complete study populations. 
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Table 10. Symptom impact of Lactobacillus rhamnosus GG in respiratory 
tract infections in studies II (n=501) and IV (n=59). 
 
 
 
In study II, in the subgroup of completed cases in terms of recovery of GG in 
faecal samples (n=128), less days with at least one respiratory symptom was 
observed in the GG group compared to the control group (4.71/month [95% 
CI 4.52–4.90] vs. 5.67/month, [95% CI 5.40–5.94], IRR 0.83; [95% CI 0.78–
0.88], P<0.001). In study III, in the subgroup of 194 children who visited the 
study physician at least once, there was significantly fewer days with 
respiratory symptoms in the GG group (6.48, 95% CI 6.28–6.68) compared 
to the control group (7.19, 95% CI 6.98–7.41) (P<0.001). There was no 
statistically significant difference in the duration of respiratory symptom 
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episodes related to a study physician visits (16 days [95% CI: 13–19] in the 
GG group vs. 18 days [95% CI 14–23] in the control group) or in the number 
of respiratory symptoms recorded by a study physician on a visit with NPS 
sample collection (3.6 [95% CI 3.3–3.8] in the GG group vs. 3.7 [95% CI 3.5–
4.0] between the GG and control groups. 
 
In study IV, on the three-week period preceding the rhinovirus challenge, 
there was a trend towards statistically significant difference between the 
groups in the total symptom score (P=0.064). All other illness endpoints 
were systematically lowest in the live GG group, but no statistically 
significant differences were detected. As this study was designed as a pilot-
study, it was calculated that with a power of 80% and at a significance level of 
0.05, 103 subjects would be needed to detect a difference in the symptom 
scores during the five days following the virus challenge. Symptom endpoints 
following the inoculation were also analysed for the subgroup of infected 
subjects (n=50). In this subgroup, the mean AUC values of the 5-day post-
inoculation symptom scores were 4.51 in the control group (95% CI 3.12-
5.91), 3.81 in the live GG group (95% CI 2.23-5.40) and 3.61 in the 
inactivated GG group (95% CI 2.21-5.01). During the 3-week post-inoculation 
period, the mean AUC value in the infected subjects was 2.28 (95% CI 1.21-
3.35) in the control group, 1.63 (95% CI 1.21-2.06) in the live GG group and 
1.63 (95% CI 1.07-2.20) in the inactivated GG group. There was no 
statistically significant difference in either of the analysed symptom scores in 
the infected subjects subgroup  (P=0.65 for both comparisons).  
5.4 EFFECT OF PROBIOTIC ON VIROLOGICAL AND 
IMMUNOLOGICAL FINDINGS (III, IV) 
Nasopharyngeal findings of respiratory viruses in symptomatic children 
(III) 
In study III, at least one NPS sample (mean 1, range 1–6) was collected from 
194 symptomatic children, who then formed the subgroup for the virological 
analyses. The total number of collected NPS samples was 315 (159 in the GG 
group and 156 in the control group), and 202 (64%) of these samples were 
positive to at least one virus. Two or three viruses were found in 14% of the 
studied samples. No statistically significant differences were found in the 
number of children who gave at least one positive sample nor in the number 
of virus positive samples between the two groups. Procentual distributions 
between the groups in positive findings per virus, from most often detected 
virus to the least frequently found, are presented in Figure 3. There was more 
PIV1 detected in the GG group compared to the control group (P=0.035), but 
also non-significant trends towards less EV (P=0.083) and AdV (P=0.095) 
findings in the GG group compared to the control group.  
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Figure 3. Distributions between the groups in viral findings presented per 
virus in study III (the number of total findings of the virus in brackets). 
Abbreviations: RV, rhinovirus; RSV, respiratory syncytial virus; PIV, 
parainfluenza virus; EV, enterovirus; IFV A, influenza A virus; ADV, 
adenovirus; HBoV, human bocavirus. 
 
 
Association of viral findings with respiratory symptoms (III)  
The mean duration of respiratory symptom episodes related to a study 
physician visit was similar in the GG group (16 days, 95% CI 13-19) compared 
to the control group (18 days, 95% CI 14-23) in the subgroup of 189 children 
from whom a study diary was received from the timing of the study physician 
visit (P=0.42). On the study visits where NPS samples were collected, the 
mean number of recorded respiratory symptoms was 3.6 (95% CI 3.3–3.8) in 
the GG group, and 3.7 (95% CI 3.5–4.0) in the control group. When numbers 
of respiratory symptoms associated with positive viral finding were analysed, 
no statistically significant differences were found between the study groups 
 
Viral cultures, antibody responses and infection rates (IV, including 
unpublished data) 
In study IV, positive viral culture was found in 48 (81%) subjects (13/19 
[68%], 18/20 [90%] and 17/20 [85%] in the live GG, inactivated GG and 
control groups respectively, P=0.20). Two of these positive viral cultures 
were identified as wild viruses (one subject in the inactivated GG group and 
one in the control group). An antibody response was observed in 31 (52%) 
subjects (9/19 [47%], 10/20 [50%] and 12/20 [60%] in the live GG, 
inactivated GG and control groups, respectively; P=0.70). Infection, defined 
as at least one positive culture on five days following inoculation and/or at 
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least four-fold rise in the antibody response to the challenge virus, occurred 
in 50 out of 59 (85%) subjects (14/19 [74%] in live GG group, and 18/20 
[90%] in both inactivated GG and control groups, P=0.36). Of the infected 
subjects, 19 had rhinovirus shedding without sero-convertion and two 
subjects did not have rhinovirus in the nasal washes but sero-conversion 
occurred. It was calculated that, if the trend of lower infection rate in the live 
GG group holds true in a larger-scale trial, 102 subjects per group would be 
needed in order to detect a difference between the live and control group, 
with a power of 80% and at a significance level of 0.05.  
5.5 COMPLIANCE (I-IV) 
In study I, the capsules of 53 subjects were available for counting as four 
subjects failed to return the leftover capsules. Of these subjects, 79% 
consumed at least 95% of the advised amount of capsules during the 
intervention. In study II, the average daily milk consumption was 4 dl in both 
groups, based on the recordings by the day care personnel and parents’ 
reporting in the study diaries. In study IV, 99.8% of the daily study product 
doses were consumed, based on the recordings of the study personnel from 
the direct surveillance of the product consumption at the study site. 
Furthermore, the recovery of GG in faecal samples indicated good 
compliance as the number of subjects with GG recovered increased in all 
groups receiving GG in all trials when the baseline and the end of trial faecal 
samples were compared.  
5.6 SAFETY (I-IV) 
In study I, symptoms during the intervention and also after the intervention 
and operation were followed as a measure of safety. Data from 70% of the 
subjects were available for the analysis of the symptoms as the rest of the 
subjects failed to return the study diary. Respiratory symptoms occurred in 
25% of the subjects (3/13, 3/12 and 4/15 in the GG, multispecies and control 
groups, respectively) and 10% of the subjects experienced GI symptoms 
(0/13, 1/12 and 3/15 in the GG, multispecies and placebo groups, 
respectively) during the intervention at least on one day, without differences 
between the groups (P=0.99 for respiratory symptoms and P=0.33 for GI 
symptoms). During the post-tonsillectomy follow-up period, there was no 
difference between the groups in the number of subjects experiencing post-
operative bleeding or pain, nor in the number of days with bleeding or pain 
between the groups (P-values 0.32, 0.40, 0.99 and 0.62, respectively; data 
not shown). There was, however, statistically significant difference between 
the groups in the total number of subjects having a temperature of >37.5oC 
post-operatively (2/13, 4/12 and 0/15 in the GG, multispecies and control 
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groups, respectively; P=0.036). Furthermore, all post-tonsillectomy blood 
cultures were negative for bacterial growth. 
 
In study II, altogether 22 adverse events were reported during the 
intervention, of which 15 were related to GI problems such as nausea or 
abdominal pain, and seven to skin problems such as rash. Of all the adverse 
events, eight occurred in the GG group (five GI related and three other) and 
14 in the control group (10 GI related and four other). None of the reported 
adverse events were serious. In study IV, 105 adverse events were reported 
during the study, and 84% of these were cold symptoms occurring prior to 
rhinovirus challenge. None of the reported adverse events were assessed as 
having a probable relationship to the study product consumption and 16 
were considered to have a possible relationship to the study product 
consumption. Of these 16 adverse events, nine occurred in the control group 
and seven in the live GG group. No serious adverse events were reported 
during any of the trials. 
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6 DISCUSSION 
The series of studies presented in this work consists of three double-blind 
randomized controlled trials, all aimed at investigating the symptom impact 
or mechanistic aspects of the widely researched probiotic, L. rhamnosus GG, 
in respiratory tract infections. The clinical manifestation of infections, 
nasopharyngeal presence of respiratory viruses, and colonization of GG in 
the upper respiratory tract were addressed as primary endpoints, and also 
probiotic viability and effects as a single strain versus as part of a 
multispecies combination were explored in specific studies. Two of the RCTs 
were pilot-scale studies, and thus aimed at collecting preliminary data. One 
of these applied a novel clinical set-up in probiotic efficacy studies, 
experimental rhinovirus challenge model. 
6.1 RECOVERY IN TONSIL TISSUE 
The present study was the first RCT to address the pharyngeal recovery of a 
probiotic strain. At the time of the protocol development of study I, only one 
unrandomized and uncontrolled pilot study on six subjects had addressed 
the tonsil recovery of a Lactobacillus strain, and shown that L. plantarum 
DSM 9843 could be recovered from a tonsil surface four hours after oral 
intake in all subjects, and after eight hours in just one subject (Stjernquist-
Desatnik et al. 2000). Furthermore, it had been previously demonstrated 
that GG possesses adhesive properties in intestinal gut mucosa (Alander et 
al. 1999; Alander et al. 1997). With this background, study I, a pilot-scale 
double-blind RCT was set-up to investigate whether an extended oral 
consumption of GG would lead to the recovery of the probiotic strain in the 
tonsil tissue, and whether the supplementation of GG as a single strain or 
together with three other probiotic strains would affect the adhesion. In this 
study GG was recovered in the tonsil tissue of less than half of the subjects 
who received GG as a single strain or as a part of the multispecies probiotic 
combination, but also in almost one third of the subjects in the placebo 
group. The recovery rates were similar for both single-strain and 
multispecies groups. Thus the present study did not give any indication that 
other probiotic strains would either boost nor hinder the adherence of GG in 
the tonsil tissue. 
 
The finding that recovery of the probiotic in the upper respiratory tract did 
not occur in all the adult subjects after the oral consumption is in line with 
the findings from studies on other probiotic strains (Power et al. 2008; 
Stjernquist-Desatnik et al. 2000). It appears that there is individual variation 
in the tonsillar adherence, as in the present study the compliance of study 
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product consumption was good, confirmed by the analysis of faecal recovery 
of the strain and counting of leftover study products. On the contrary, in 
children three weeks GG consumption led to the recovery of the strain in all 
subjects’ adenoid tissue (Swanljung et al. 2015). Based on this it can be 
speculated that the adherence in the upper respiratory tract might be more 
effective in children, or that there are disparities in the adherence in different 
areas. Mechanisms of probiotic adherence in the upper respiratory tract 
mucosa have not been studied but it is likely that pili structures of GG have a 
crucial role in adherence similarly as in the gut (Lebeer et al. 2012). In the 
middle ear, GG has been recoverable in only fifth of the children (Tapiovaara 
et al. 2014). Mechanisms by which GG migrates from the nasopharynx to the 
middle ear are not known, but based on the recovery rates it appears that the 
invasion mechanism is not fully effective.  
 
The high rates of GG recovery in the faecal and tonsil samples in the control 
group at the end of the intervention were unexpected, as only one subject 
with a positive faecal recovery and none with positive tonsillar recovery in 
the control group reported accidental one-time consumption of products 
containing GG. Furthermore, two thirds of the subjects in the control group 
with a positive tonsillar recovery of GG had GG recovered from the faecal 
sample already at the start of the intervention. This raises the speculation on 
the possibility of a persistent colonization of GG in the upper respiratory 
tract. GG has been documented to be recoverable from the faecal samples by 
PCR methods in almost one third of adults three weeks after consumption 
has ceased (Saxelin et al. 2010) and in one quarter of infants six months after 
the intervention (Gueimonde et al. 2006). Cases with GG colonization 
persisting up to 18 months (Gueimonde et al. 2006) and up to 24 months 
(Schultz et al. 2004) have also been reported. The finding of high 
nasopharyngeal recovery of GG in the control group is not unique. Even a 
higher recovery rate of GG was found in the control group in a study on 
adenoid tissue recovery in children, with similar study set-up to the present 
trial (Swanljung et al. 2015).  In this study GG was recovered from three 
quarters of the control adenoid samples. It could be that the persistence of 
GG is stronger in children compared to adult subjects or persistence might 
differ in different parts of the upper respiratory tract mucosa.  
 
Even though no studies have yet addressed the issue, it is plausible that 
nasopharyngeal probiotic colonization would have an effect on the 
microbiota residing in the upper respiratory tract. In terms of the intestinal 
microbiota, a follow-up study on the cohort from study II recently 
demonstrated that GG does influence the intestinal microbiota in children 
and also appears potent to prevent some the changes resulting from 
antibiotic use (Korpela et al. 2016). Understanding of the airway microbiota 
as a whole is still incomplete (Taylor et al. 2016). It has been concluded that 
the nasopharyngeal microbiota can have an impact on the risk of developing 
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RTIs (Biesbroek et al. 2014; Hasegawa and Camargo 2015). Furthermore, the 
severity of acute respiratory symptoms has been shown to be associated with 
the microbiota composition (Teo et al. 2015). It was recently presented that 
for instance RSV interaction with the nasopharyngeal microbiota modulated 
the host immune response and had an impact on the clinical disease severity 
(de Steenhuijsen Piters et al. 2016). The role of the airway microbiota, 
regulating local immune functions, and the gastrointestinal microbiota, 
affecting the respiratory immunity (Taylor et al. 2016) in RTIs and the 
possibility of probiotics to beneficially modify both is an interesting future 
research area.  
 
Methodological considerations 
Subjects recruited to study I were young adult patients about to undergo 
tonsillectomy due to chronic or recurrent tonsillitis. The subjects represented 
only a small age group of 18-30 year-olds, and results might differ in other 
age groups. Adhesion could be affected for instance by the tonsillar 
microbiota, which has been shown to be different in children and adults 
(Gaffney et al. 1991; Loganathan et al. 2006). Furthermore, the health status 
of the subjects in the present study, history of recurrent or chronic tonsillitis, 
is also known to impact the tonsillar microbiota (Jensen et al. 2013). Thus it 
cannot be outruled that the results could differ in subjects without any 
history of tonsillitis or in other age groups.  
 
Due to the pilot nature of the study, it was short in duration, with 
intervention lasting only three weeks, and run-in period, without the 
consumption of probiotic products, for one week. This was considered 
adequate because events during the intervention were not an efficacy 
endpoint, and time from the start of the run-in to tonsil sample collection 
was four weeks, which was estimated as long enough for any probiotic 
colonization originating from the time preceding the trial to clear off. As high 
recovery rates were detected in the control group, a longer run-in period 
should be applied in future studies, but role of the unconscious GG 
consumption during the run-in and intervention periods cannot be ruled out 
as the source of GG colonization in the control group.  
 
Regarding the detection method of GG in the tonsil samples, the original aim 
was to use strain specific GG quantification for tonsil samples, similarly as 
was done for faecal samples. However, when tonsil samples were collected, 
the tissue was divided into several pieces and surface and core were not 
identified. Therefore it was considered in the analysis phase that 
quantification would not give trustworthy results due to the possible 
differences in the amount of the tissue surface in the analysed pieces, and 
simple real-time PCR was carried out instead.  
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Taken together, GG can be recovered from tonsil tissue after oral 
consumption in some but not all adult subjects, and it thus 
appears that individual variation exists in the attachment to tonsil 
tissue. Colonization might also be persistent at least in some 
subjects. Combining GG with other strains does not seem to affect 
the adhesion rate. Due to the possible individual variation in the 
tonsillar colonization of GG, future studies combining the follow-
up of respiratory tract infection endpoints to the analysis of GG 
recovery in the upper respiratory tract would be of interest.  
6.2 SYMPTOMS OF RESPIRATORY TRACT INFECTIONS 
Prior to the studies II and IV, the effects of GG in RTIs had only been 
addressed in one study on children (Hatakka et al. 2001) and one in adult 
marathon runners (Kekkonen et al. 2007). The present studies were 
conducted to clarify the findings of the previous trials, as well as to increase 
understanding behind the health effects, if these were to be observed. In the 
present studies, GG supplementation was not able to significantly affect the 
clinical manifestation of RTIs in healthy children attending day care (II), nor 
in healthy adults challenged to RV (IV). In children, there was no difference 
observed in the number of days with respiratory symptoms, nor in the 
number of episodes between the GG and control groups. However, when 
numbers of days with respiratory symptoms were explored in the “completed 
cases” subgroup of children based on the recovery of GG in faecal samples 
(II), or in the subgroup of children taken to a study physician during the 
intervention (III), children in the GG group had less symptomatic days. In 
adults, the study does not provide a definitive answer on the efficacy of GG in 
RV infections as it was designed as a pilot-scale trial and thus not powered to 
detect a statistically significant difference between the groups, but the 
symptom endpoints systematically favoured the group receiving live GG. 
Based on a post-trial power calculation, an RCT with over 100 subjects per 
group would be needed to detect a statistically significant difference in the 
symptoms scores between the live GG and the control group, assuming that 
the observed trends would hold true in the large-scale trial.  
 
The results of the present study II are conflicting with the studies on GG that 
have demonstrated significant respiratory symptom reduction in children 
(Hojsak et al., 2010a; Hojsak et al., 2010b; Luoto et al., 2014), and more in 
line with the modest trends detected in one study (Hatakka et al. 2001). One 
possible explanation for conflicting results is the daily GG dose. The dose has 
been on average 108 cfu per day in the interventions that have resulted in the 
more modest or no effects (Hatakka et al., 2001; study II) and 109 cfu in the 
studies where clear benefits have been demonstrated (Hojsak et al., 2010a; 
Hojsak et al., 2010b). No dose-response studies have been conducted on 
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respiratory infections for any probiotic strain, and thus the effect of the dose 
can only be speculated. Dose-response of GG has been investigated in GI 
infections, but only using higher doses (1010 and 1012 cfu/d), resulting in both 
doses being effective (Basu et al. 2009). For other strains with dose-response 
studies also with lower doses, it has been shown for instance that dose of 1010 
cfu but not 108 cfu per day of a four-strain probiotic combination was 
effective in reducing AAD (Ouwehand et al. 2014). Recent study on infants 
interestingly showed that daily GG supplementation of 109 cfu/d only during 
the first two months of life was able to have an effect on RTI episodes during 
the first year of life (Luoto et al. 2014). Furthermore, a follow-up study on a 
subgroup of children from study II showed that GG appeared to prevent 
some bacterial infections for up to three years following the intervention, 
indicated by reduced antibiotic purchases (Korpela et al. 2016). In study II, 
in contrast to a previous trial on GG with similar trial setting (Hatakka et al. 
2001), probiotic product was also given to subjects to be consumed at home 
on the days when a child was not attending day care, such as weekends, 
holidays and absences due to illness. It was hypothesized that the daily 
consumption would boost the health effect compared to consumption only in 
day care, but results of the present study do not support the hypothesis. 
These findings indicate that doses of at least 109 cfu/d appear to be more 
effective, but more research is needed to identify the optimal dose and its 
long-term impacts in terms of health effects, feasibility and cost-effectiveness 
in RTIs. 
 
The need to explore the “completed cases” subgroup separately in study II 
rose from the observed relatively high number of children with GG recovered 
from the faecal sample at the beginning of the intervention as well as 
numerous faecal GG detections in the control group at the end of the 
intervention. These findings were speculated to affect the results of the trial. 
It seems clear that the two to three week run-in period was not sufficiently 
long to clear off GG, and during the intervention children in the control 
group were either ingesting GG unconsciously via some other products, even 
though families had a list of products with GG to be avoided, or GG 
colonization persisted throughout the intervention in some children. In a 7-
month GG intervention study, 9% and 15% of children in the control group 
had GG-like bacteria recovered from the faecal samples using cultivation 
methods at four and seven months, respectively (Hatakka et al. 2001). 
Furthermore, in children who had received GG during first six months of life, 
GG was still recovered in one quarter of the infants six months after the 
intervention, and few of these children still carried the strain 18 months after 
the intervention (Gueimonde et al. 2006). In this study, the subjects with GG 
recovered from faecal samples after the intervention had decreased 
frequency of atopic eczema at two years of age compared to the subjects 
without GG detected in the faeces (Gueimonde et al. 2006). In study II, the 
effects of GG supplementation were similarly more emphasized in the 
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“completed cases” subgroup. Not a lot is known about how the possible 
prolonged GG colonization affects the health outcomes in vivo. It has been 
shown that early life probiotic consumption can have long term impact on 
RTIs (e.g. Luoto et al. 2014), hypothesized to be incurred through timely 
immunomodulation during the  “programming” of the immunologic 
phenotype, but it is not known if beneficial effects could be reflected as long-
term probiotic colonization.  
 
The children taken to a study physician at least once (III) had more days with 
respiratory symptoms compared to the total group of followed subjects (II), 
and the RTI episodes were longer, thus indicating that this subgroup 
represented children more effected by RTIs. In this subgroup of more 
symptomatic children, a significant reduction in the number of days with RTI 
symptoms was observed in children in the GG group compared to those in 
the control group, although there was no difference in the number of study 
physician consultations between the groups. This suggests that GG might 
incur some minor symptom reducing effects in children more prone to 
infections, even if effects are not significant enough to reduce more severe 
infections that require physician consultation. Previously a GG-including 
probiotic combination was unable to reduce AOM-episodes in otitis-prone 
children, but daily symptom data was not reported (Hatakka et al.). No other 
studies have addressed the effects of probiotics in RTI-prone subgroups, and 
thus future research on the issue is warranted, with follow-up and reporting 
of daily symptoms in addition to physician-diagnosed infections and 
infections episodes. 
 
The results of the pilot-scale trial on adults (IV) implied that GG might be 
effective in reducing RTI symptoms also in healthy adults, but findings were 
not statistically significant and need to be assessed in an appropriately 
powered study. Previously, the effects of GG on respiratory symptoms in 
adults have only been addressed in marathon runners, where no effect was 
demonstrated (Kekkonen et al. 2007). Authors concluded that with the study 
being conducted during summertime when pathogen exposure is low, can the 
effect of GG, which is likely to be small, be impossible to see, even if it would 
exist. The post-trial power-calculation of study IV, which indicated that over 
100 subjects per group would be needed to confirm if the observed trend 
between GG and control group would hold true in the large-scale trial, 
demonstrates that if GG has an effect in adults in reducing RTIs, the effect is 
likely to be small, requiring large study populations, even in the challenge 
model exposing all subjects to a virus. However, no difference between the 
groups was seen in the diagnoses of a cold, determined based on predefined 
symptom scoring and the subjective impression of having a cold. In terms of 
other probiotic strains, there is indication that some strains, most notably L. 
casei Shirota, could reduce RTIs significantly also in healthy adults (Shida et 
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al. 2015), but majority of probiotic studies on RTIs in adult populations have 
shown negative results. 
 
In the present study (IV), respiratory illness endpoints were systematically 
on a lower level in the live GG group, and thus it suggests that inactivated GG 
is not as effective as the live strain. However, the pilot-scale of the study 
allows only hypothesis creation and no final conclusions can be drawn based 
on it. It is possible that the superiority of live GG would be mediated through 
the lower rhinovirus infection rate in the live GG group, as when results were 
analysed only for the infected subjects, live and inactivated GG were on 
similar levels in symptom scores, both groups still maintaining a lower level 
compared to the control group. Based on these findings it can be speculated 
that perhaps only live GG is able to prevent the infection altogether for 
instance by binding directly to the virus, whereas both live and inactivated 
forms are able to modulate the immune response and thus reduce the 
symptom impact of the viral infection. In vitro and animal models have 
previously suggested that similar immunomodulation patterns would occur 
with both live and inactivated strains (Li et al. 2009; Lopez et al. 2008; 
Zhang et al. 2005).  
 
Methodological considerations 
Subjects in studies II and IV did not have serious illnesses, and results thus 
apply to healthy population in the studied age groups. Subjects in study II 
were children aged two to six years old attending day care, thus covering the 
most significant age groups in day care, and making the study group 
representative of children attending day care in Finland in general. Despite 
randomization, there was slightly more atopic eczema in the placebo group 
compared to the probiotic group. A previous stydy has found that effect of 
GG is more pronounced in children with a history of allergic diseases 
(Hatakka, 2007b). Furthermore, there were slightly more adenoidectomies in 
the probiotic group compared to the placebo group. However, there were no 
differences in the infections rates between the groups during the past 12 
months preceding the trial, and thus it can be presumed that groups were 
similar in terms of their proneness to RTIs. The median number of months 
children had attended day care before the trial was four months more in the 
GG group compared to the control group. However, results regarding the 
effect of the length of the day care attendance on RTIs are conflicting 
(Hatakka et al. 2010; Hurwitz et al. 1991), and thus it is difficult to conclude 
to which direction the difference could possibly have skewed the results. 
Subjects in study IV were healthy, mainly young adults. There is no 
indication that respiratory illness would be significantly different within 
adults of different ages (excluding the elderly), thus making the results 
relevant for healthy adult population in general. 
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In study II, the sample size estimated to be required to demonstrate a 
statistically significant difference between the groups could not be met. The 
intervention was set to start by latest at the beginning of October 2009 before 
the peak respiratory infection season. Owing to limited time available for the 
recruitment and unexpectedly challenging recruitment of subjects, the 
sample size goal could not be met despite extensive expansion of the study 
area and inclusion of altogether 60 day care centres. The number of 
randomized subjects was 87% and those with primary outcome data available 
84% of the sample size that according to pre-study power calculation would 
have been needed to detect a statistically significant difference between the 
groups. Furthermore, the effect size was smaller than expected. Study IV was 
designed as a pilot-scale trial, and no power calculation was performed, and 
thus no statistically significant differences between the groups in the 
followed endpoints were expected. In study II, only subjects with at least one 
primary outcome data available, in practise meaning one study diary filled 
out by parents including the respiratory symptom data, were included in the 
analysis. The approach can be criticised for not fulfilling the intention-to-
treat criteria. However, also excessive imputation of data should be avoided, 
and thus the exclusion of subjects from whom no primary outcome data was 
available from analyses was considered as the best option available for 
undistorted results.  
 
The symptoms of respiratory tract infections were evaluated and reported by 
the parents of the children in study II and by both the subjects themselves as 
well as by the study nurse in study IV. In study II, the daily symptom 
questionnaire in the study diary was unvalidated. The CARIFS scale (Jacobs 
et al. 2000) would have been a validated option, but lack of awareness of the 
scale, due to rare use in clinical trials at the time, led to it not being 
considered as an option in the protocol design phase. In retrospect, it would 
have been a possible option, although linguistic validation to Finnish would 
have been required. It would also have been slightly more laborious for the 
families, which could have been a challenge due to the length of the trial. The 
chosen form of symptom monitoring was based on a study diary used in a 
previous trial with similar trial setting (Hatakka et al. 2001), and thus its 
usability had been tested in practise in a long intervention trial. Another 
drawback in the symptom follow-up was that severity of symptoms was not 
assessed, but merely if a symptom was present or not. In study IV, data on 
the common colds was collected using the Jackson scale (Jackson et al. 
1958), which has been successfully used for decades in clinical trials 
investigating the common cold. From societal perspective, a drawback of the 
Jackson scoring is that it does not measure functional impairment or quality-
of-life (Barrett et al. 2006). To overcome this the method could have been 
supplemented with the use of WURRS that specifically assesses illness-
specific quality-of-life outcomes in adult cold sufferers (Barrett et al. 2009; 
Barrett et al. 2002). Overall challenge with symptom questionnaires and 
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their validation is that there is no gold standard for assessing RTIs (Barrett et 
al. 2006). However, strive towards the implementation of validated forms of 
RTI follow-up should be taken to increase the quality and comparability of 
the data. 
 
One challenging aspect in RTI studies is defining infections. For subject-
reported symptom data, the most common approach is to report either the 
occurrence of all respiratory symptoms or episodes, defined using varying 
criteria. In some studies physicians verify the infections, but this again can be 
done according to varying methods. Closer virus type followup has also 
shown that new episode can begin already during the previous one (Peltola et 
al. 2013), which can further complicate the interpretation of episode data and 
thus support symptom days as a preferable endpoint. In study II, symptom 
days, episodes and physician diagnoses were all reported to give a versatile 
picture of the illness rates in the study population. In study II, episode was 
defined by at least one respiratory symptom on two consecutive days or at 
least two symptoms on one day. Similar criteria have been applied also in 
other probiotic studies (Kekkonen et al., 2007; Tiollier et al., 2007; Taipale et 
al., 2011; Hatakka et al., 2007a). In addition, seven symptom-free days were 
required in between two episodes. Some studies have applied the same one 
week requirement (Hatakka et al., 2007a), but shorter periods, e.g. three 
asymptomatic days sufficing to separate two episodes have also been 
reported  (Kekkonen et al. 2007), and many publications do not specify the 
length of this period at all, implying that possibly only one symptom-free day 
is considered enough to separate different episodes. The number of episodes 
detected in study II, approximately four during the whole 28-week follow-up 
during which most annual respiratory infections occur, is in line with the 
higher end of RTI incidence reported in previous trials for pre-school aged 
children (Chonmaitree et al. 2008; Lönnrot et al. 2015; Nokso-Koivisto et al. 
2002; Shapiro 1998), but more than in some of the reports (Grüber et al. 
2008; Monto et al. 2014). It is logical that the incidence is in the higher end 
of the scale as the subject were attending day care, which is known to 
increase the incidence of RTIs (Ball et al. 2002). These findings suggest that 
the episode criteria used in study II reflected the epidemiological findings. 
 
To summarize, GG did not significantly reduce the clinical 
manifestations of RTIs. The results imply that in children, 
proneness to infections could increase and intestinal GG 
colonization originating from outside the trial minimize the 
possible small symptom impact of GG, but it was clearly shown 
that the used dose could not reduce the clinically defined infection 
cases. Use of a lower GG dose than what has been applied in 
previous studies on children with positive results is one possible 
factor behind the negative results.  Preliminary pilot-scale results 
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suggest that live GG is a more promising option compared to 
inactivated strain in reducing RV infections in adults.  
6.3 VIRAL PATHOGENS OF RESPIRATORY TRACT 
INFECTIONS 
Study III was the largest probiotic trial based on the number of subjects to 
analyse viral aetiology including all the common causative viruses in RTIs, 
and study IV was the first viral challenge study addressing probiotic efficacy. 
No significant differences in viral findings were observed in the symptomatic 
children attending day care (III) or in the healthy adults challenged with RV 
(IV). In the child cohort, probiotic and control groups did not differ in the 
number of symptomatic children with at least one positive viral finding, the 
number of virus positive samples or the occurrence of most of the individual 
respiratory viruses analysed from the NPS samples (RV, RSV, IFV A 
(H1N1)pdm09, IFV A(H3N2), IFV B, PIV2–3, and HBoV1–4). PIV1 appeared 
to occur less frequently in the control group, and EV and AdV less frequently 
in the GG group. No difference was seen between the groups regarding the 
major pathogen, RV. Oppositely, a recent study on GG in preterm infants 
showed a significant reduction in RV-induced infections during the first year 
of life, but no effect was seen on the presence of other respiratory viruses 
(Luoto et al. 2014). In comparison to findings of study III, in the study by 
Luoto et al PIV1 was not recovered in any of the samples in symptomatic or 
asymptomatic infants, and no difference was observed between the groups in 
EV or AdV-findings. Similarly to the present study, in symptomatic military 
conscripts GG and B. animalis supsp. lactis Bb-12 combination did not 
reduce the detection rates of any of the analysed respiratory viruses 
(Lehtoranta et al. 2014). In asymptomatic children, GG has not had an effect 
on the presence of common respiratory viruses (Luoto et al. 2014; Swanljung 
et al. 2015; Tapiovaara et al. 2014), whereas probiotic combination 
containing GG has reduced HboV in otitis-prone children (Lehtoranta et al. 
2012). In the present symptomatic cohort, no effect on HboV findings was 
seen. 
 
In the adult population challenged with RV, the number of positive viral 
cultures and infection rate (defined by either positive viral cultures and/or 
rise in the antibody response) were lowest in the group consuming live GG, 
but the study was pilot-scale trial and difference was not statistically 
significant (IV). Inactivated GG had no effect on the before mentioned 
parameters. The recently demonstrated reduction in RV-induced infections 
in preterm infants makes this promising findings on live GG specifically 
interesting (Luoto et al. 2014). From the present adult study population (IV), 
also RV loads have been analysed, demonstrating the lowest RV loads in the 
live GG group (Tapiovaara et al. 2016a). Interestingly, no effect on RV load 
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was seen in the study on preterm infants (Luoto et al. 2014). Even though no 
effect was observed for GG in RV-reduction in the symptomatic children 
(III), further research to clarify ability to GG to reduce RV-induced infections 
or RV loads is warranted to clarify the conflicting results. 
 
The nasopharyngeal microbiota can influence not just the pathogen 
colonization but also the disease process after pathogen colonization, such as 
symptom severity (de Steenhuijsen Piters et al. 2016; Teo et al. 2015). It has 
already earlier been demonstrated that upper respiratory tract microbiota 
has a role in the regulation of virulence that can occur also without 
differences in pathogen colonization (Roos et al. 2001). Thus it should be 
noted that lack of difference between the probiotic and control groups in the 
respiratory virus findings does not rule out clinical effects. In study III, 
symptom severity was not measured, but the fact that both groups consulted 
study physicians at equal frequency suggests lack of or at best minor 
differences in infection severities. Interestingly there was an overall lower 
symptom rate observed, but as no nasopharyngeal samples were taken 
outside the physician consultation, the present data is not able to clarify if 
differences in pathogen counts would have explained the symptom reduction 
in cases which did not lead to physician consultation. As this subgroup could 
be considered more prone to infections due to the higher symptom rate, it is 
of interest that in otitis-prone children, trend towards a lower number of 
HboV findings was detected in asymptomatic children consuming GG-
including probiotic combination compared to the control group (Lehtoranta 
et al. 2012), even though the occurrence of AOM was not reduced in the same 
study population (Hatakka et al. 2007a). In that trial, differences in the daily 
symptoms were not reported by intervention groups, and thus findings 
cannot be fully compared to the present study. However, the majority of the 
results on GG’s effect on viral findings in asymptomatic children have been 
negative (Luoto et al. 2014; Swanljung et al. 2015; Tapiovaara et al. 2014). 
 
Methodological considerations 
Subjects in study III consisted of children who visited the study physician at 
least once, and this subgroup represented subjects suffering from more 
respiratory symptoms and longer episodes compared to the complete study 
population, thus representing children more affected by RTIs. The study was 
designed to follow the patterns of normal health seeking behaviour, and thus 
parents were instructed to take the child to a study physician only in the 
cases when they would normally seek consultation. It is therefore likely that 
many mild infections were treated at home, and are thus not represented in 
the analysed samples. It should, however, be noted that these factors 
affecting health seeking behaviours have most likely affected the two groups 
in a similar manner. It is also possible that some samples were missed if 
parents for instance due to practical reasons consulted a physician who was 
not involved in the study. 
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All study staff collecting specimens were instructed to take samples in a 
similar manner and to follow guidelines regarding sample storage and 
transportation. Analysis procedures used validated PCR-methods. 
Furthermore, the reliability of analysis results is further supported by the 
facts that findings of respiratory viruses in study III followed the typical 
seasonal pattern and in study IV infection rate achieved with the model in 
the control group was similar compared to the previous studies. 
 
Taken together, GG was not effective in reducing the overall 
presence of common respiratory viruses in the nasopharynx of 
symptomatic children. A pilot-scale RV challenge trial in adults 
suggested possibility for the effectiveness of live GG, but due to 
the small scale of the trial no firm conclusions can be drawn. Data 
in the area remains scarce and conflicting, GGs ability to reduce 
symptomatic RV infections appearing most promising. To clarify 
the data currently available, it would be of relevance to include 
viral detection also in future GG trials in RTIs, ideally also in the 
cases of mild infections and including the detection of viral loads. 
6.4 SAFETY  
In study II, very few adverse events were reported and the majority of them 
occurred in the control group. In study IV, a higher number of adverse events 
were reported, likely due to the methodological differences, as in study IV 
subjects were asked daily by the study personnel of any adverse events and 
also cold symptoms occurring before the rhinovirus inoculation were 
reported as adverse events. However, no adverse events had a probable and 
only 16 has a possible relationship to the study product consumption, most of 
them occurring in the control group. Recently published analysis on the 
adverse events of six GG trials, one of which was study II, also demonstrated 
the safety of GG in healthy individuals (Tapiovaara et al. 2016b). In study I 
on tonsillectomy patients, more post-operative fever was observed in the GG 
groups, but no bacteraemia cases occurred in the study population. In a 
recent study, post-tonsillectomy bacteraemia was detected in 2.1% of patients 
(Shishegar and Ashraf 2014), and previously rates as high as 25% have been 
reported (Kaygusuz et al. 2001). In the earlier study, 70% of bacteraemia was 
caused by bacterium recovered on a tonsil surface and in deep tissue cultures 
(Kaygusuz et al. 2001). In the more recent study, the growth of the same 
potentially pathogenic bacteria were found in both blood and tonsillar tissue 
cultures, suggesting that bacteraemia could originate from the bacteria 
present in tonsillar tissue (Shishegar and Ashraf 2014).  In study I, all post-
tonsillectomy blood cultures were negative for bacterial growth, and further 
correlation of GG findings in tonsil tissue to blood cultures was not required.  
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To conclude, the results from this work support the safe use of GG 
in healthy subjects.  
6.5 CONTEXT OF FINDINGS AND CONSIDERATIONS 
FOR FUTURE TRIALS 
The sosio-economic burden of RTIs is high, due to their frequency of 
between two and five episodes in small children to approximately one in 
adults per year, and lack of effective preventive or treatment options 
available in the majority of the cases because of viral aetiology. For large part 
are symptoms of RTIs, such as runny and stuffy nose, sore throat and cough, 
merely a nuisance, but also a risk for a very severe illness is present, 
especially when the lower respiratory tract is affected. Physical interventions, 
especially hand washing, remain the central strategy for preventing the 
spread of the respiratory viruses, but such nutritional interventions that have 
a low risk for adverse effects and a low cost of implementation could have 
significant impact on the socioeconomic burden of RTIs on the population 
level, even if effects are modest on an individual level. Recent meta-analyses 
have concluded that probiotics could help to reduce RTI burden (Hao et al. 
2015; King et al. 2014). Even economic modelling has been performed 
concluding a significant budget impact of probiotic consumption (Lenoir-
Wijnkoop et al. 2015), but analysis of the individual studies reveals 
inadequate data regarding specific strains and target populations. 
 
The results of this work on GG add to the conflicting data on the effects of the 
probiotic in RTI prevention and symptom alleviation. Instead of confirming 
the mainly positive previous findings of GG in children, study II showed no 
effect on the RTI outcomes on the total population of children. However, two 
explorative subgroup analyses showed almost one day less per month with 
respiratory symptoms, and thus further research is warranted, as GG 
remains the strain with most promising effects in children (Luoto et al. 2014; 
Hojsak et al. 2010a; Hojsak et al. 2010b; Hatakka et al. 2001) together with 
B. animalis subsp. lactis Bb12 that has recently demonstrated positive results 
in infants (Taipale et al. 2011; Taipale et al. 2016), but not in children 
(Hojsak et al. 2015a; Hojsak et al. 2015b). Study III showed no effect for GG 
on viral findings, even though the effect on rhinovirus findings was recently 
seen in infants (Luoto et al. 2014). Furthermore, study IV suggested, in a 
controlled setting, the possible ability of GG to have an effect against 
rhinovirus, even though the pilot-scale of the study did not allow drawing of 
any firm conclusions. Thus, also the aspect of pathogen counts should be 
clarified in new trials. Study I offered an interesting insight to the ability of 
GG to adhere to the pharyngeal mucosa in only part of the subjects; a factor 
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which role in responsiveness to probiotic supplementation in RTIs would be 
of interest to address in future trials. 
 
Taking into account the distribution of the RTI burden and the results on 
GG, it would be of greatest relevance to see the probiotic research on RTIs 
focusing on infants and children in the future. It was recently demonstrated 
that only 2-month intervention in the very beginning of life could have effects 
on RTI outcomes during the first year of life (Luoto et al. 2014). These type of 
cost-effective and feasible supplementation strategies should be further 
explored and compared to continuous supplementation. Previous data on GG 
has shown that doses of at least 109 cfu/day yield better results, and thus it is 
not advisable to use doses lower that this in future studies, and ideally a 
dose-response intervention should be carried out in the future. An often side-
lined aspect in clinical trials is the manufacturing method of the study 
products, which can have an effect on the probiotic properties (Grześkowiak 
et al. 2011), and therefore rigorous quality control and reporting of 
production details in publications should be applied. The currently available 
data, to which study IV contributed, does not encourage the use of 
inactivated strain in future trials, even though data is still scarce.  
 
Furthermore, since there are implications that probiotic consumption during 
infancy could affect the RTI outcomes (Luoto et al. 2014), if other population 
groups than infants are studied, data regarding probiotic use earlier in life is 
critical to collect. This type of data is naturally subject to recall bias, but as 
probiotics are freely available, there is no other means to control their use 
retrospectively. Even if infants are the target group and probiotic 
consumption preceding the study is not a challenge, a careful follow-up of 
probiotic intake other than the study product should be applied, especially if 
the trial is conducted in a country with high probiotic product availability 
such as Finland.  
 
The adherence and persistence of GG recovery also deserve attention in 
future studies. As study I suggested, there might be individual variation in 
the probiotic adherence in the upper respiratory tract, and thus the effect of 
the adherence on the airway microbiota and the role in RTIs would be of 
interest to address. Also the assessment of faecal recovery is suggested, as it 
can possibly have an effect on the clinical outcomes, like study II 
preliminarily suggested. Furthermore, the run-in period of over three weeks 
without consumption of probiotic products is warranted if the aim is to clear 
off prior GG colonization. Study II demonstrated that approximately one 
third of the subjects still carried GG in faeces after the 2-3 week run-in 
period.  Collection of both nasopharyngeal and faecal samples for GG 
quantification at several time points during the trial would be of interest to 
clarify the role of GG adherence, persistence of colonization and correlation 
to clinical RTI endpoints. Explorative subgroup analysis in study II indeed 
 87 
suggested that clearing off the “uncompleted” cases based on faecal GG 
recovery from the study population, be it due to persistent colonization or 
incompliance, had an effect on the clinical outcomes. 
 
Another challenging aspect in RTI trials, not just on probiotics but in general, 
is the wide variety of endpoints and criteria for these used in the studies, 
which makes the comparison of results challenging. First step to clarify this 
in the future would be the wider application validated questionnaires such as 
WURSS or CARIFS. The former is more targeted for measuring the illness 
specific quality of life, but the latter is specifically targeted for measuring 
colds in children. The next step would then be to harmonize the criteria for 
RTI endpoints. The present work also suggested that simply reporting days 
with symptoms is of interest in order to better understand the likely modest 
effects of GG in RTIs, and ideally also symptom severity assessment should 
be included. 
 
To follow the results of the present work and other data published of GG in 
RTIs, and taking into consideration the challenges mentioned in this chapter, 
an ideal way forward in this research area would be to conduct a prospective 
randomized, controlled and double-blind birth cohort study with follow-up 
lasting throughout childhood to cover the years with the highest RTI burden. 
Preferably GG supplementation during only the first few months of life would 
be compared to continuous supplementation, although this would surely 
propose a challenge in the time scale suggested. In addition to the follow-up 
of the symptoms using a validated questionnaire, faecal and nasopharyngeal 
samples would be collected at regular intervals, to study persistence of GG 
colonization, its effect on the airway microbiota and its role in symptom 
endpoints. Ideally also infection aetiology would be assessed, in both mild 
and more severe cases. If overall results would be positive, economic 
evaluations of the interventions should be performed. Ideally societal 
perspective, which aims to look at the costs of an intervention to the society 
as a whole, should be applied in the evaluation. With appropriately calculated 
power, taking into consideration the relatively high drop-out rates of such 
study set-ups, this type of cohort would offer high-quality data to either 
substantiate or challenge the current understanding of potential modest 
benefits of GG consumption in reducing the symptom burden caused by 
RTIs, and if the approach would be cost-effective from a societal perspective. 
  
 88 
7 CONCLUSIONS 
The studies included in this work addressed the clinical outcomes of 
Lactobacillus rhamnosus GG consumption in respiratory tract infections in 
children and adults. Based on the results, the following conclusions can be 
drawn: 
 
1. L. rhamnosus GG could be recovered from the tonsil tissue of young 
adults after three week oral consumption as a single strain or as part 
of a multispecies probiotic combination, but only in less than half of 
the subjects receiving the probiotic. 
 
2. L. rhamnosus GG did not reduce respiratory tract infections in healthy 
children attending day care. This finding, partially conflicting with 
previous results from studies mainly on higher daily doses, needs to be 
clarified in further studies. Explorative analysis on specific subgroups, 
completed cases based on faecal GG recovery and subjects who visited 
a study physician due to an infection during the trial, suggested that 
GG could reduce the number of days with respiratory symptoms, 
warranting further research to clarify the role of GG colonization and 
susceptibility to infections. 
 
3. L. rhamnosus GG did not reduce viral findings in the nasopharynx of 
symptomatic subjects, or reduce the number of symptoms associated 
with the viral findings.   
 
4. The experimental rhinovirus model was demonstrated a functional 
controlled approach to studying probiotic efficacy in viral respiratory 
tract infections. The pilot-scale results favored the live L. rhamnosus 
GG over the inactivated form of the strain in reducing infections ans 
symptoms, but larger-scale trial would be needed to see if significant 
difference between the groups exists. 
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